Tilray Brands (TLRY) 10-Q 9 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 09, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	TLRY
Entity Registrant Name	Tilray, Inc.
Entity Central Index Key	0001731348
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		133,526,319
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38594
Entity Tax Identification Number	82-4310622
Entity Address, Address Line One	1100 Maughan Road
Entity Address, City or Town	Nanaimo
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V9X IJ2
City Area Code	844
Local Phone Number	845-7291
Entity Interactive Data Current	Yes
Title of 12(b) Security	Class 2 Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 155,205	$ 96,791
Accounts receivable, net of allowance for credit losses of $826 and provision for sales returns of $1,212 (December 31, 2019 - $615 and $1,400, respectively)	24,805	36,202
Inventory	89,917	87,861
Prepayments and other current assets	28,154	38,173
Assets held for sale	6,797
Total current assets	304,878	259,027
Property and equipment, net	187,630	184,217
Operating lease, right-of-use assets	18,460	17,514
Intangible assets, net	180,853	228,828
Goodwill	159,595	163,251
Equity method investments	8,911	11,448
Other investments	22,710	24,184
Other assets	4,324	7,861
Total assets	887,361	896,330
Current liabilities
Accounts payable	26,137	39,125
Accrued expenses and other current liabilities	32,526	50,829
Accrued lease obligations	3,230	2,473
Warrant liability	71,636
Total current liabilities	133,529	92,427
Accrued lease obligations	30,075	29,407
Deferred tax liability	48,090	53,363
Convertible notes, net of issuance costs	438,154	430,210
Senior Facility, net of transaction costs	45,944
Other liabilities	4,852	5,652
Total liabilities	700,644	611,059
Commitments and contingencies (refer to Note 18)
Stockholders’ equity
Additional paid-in capital	911,171	705,671
Accumulated other comprehensive income	2,689	9,719
Accumulated deficit	(727,156)	(430,130)
Total stockholders’ equity	186,717	285,271
Total liabilities and stockholders’ equity	887,361	896,330
Class 1 common stock [Member]
Stockholders’ equity
Common stock value		2
Class 2 common stock [Member]
Stockholders’ equity
Common stock value	$ 13	$ 9

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Allowance for doubtful accounts receivable	$ 826	$ 615
Provision for sales returns	$ 1,212	$ 1,400
Class 1 common stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	233,333,333	250,000,000
Common stock, shares issued	0	16,666,667
Common stock, shares outstanding	0	16,666,667
Class 2 common stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	133,289,944	86,114,560
Common stock, shares outstanding	133,289,944	86,114,560

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 51,406	$ 51,101	$ 153,922	$ 120,043
Gross profit	3,739	15,853	9,190	33,511
General and administrative expenses	12,665	20,122	49,030	49,618
Sales and marketing expenses	10,000	16,974	40,709	39,161
Research and development expenses	921	2,315	2,831	4,891
Stock-based compensation expenses	8,080	8,644	23,404	22,303
Depreciation and amortization expenses	3,425	3,200	10,353	7,457
Impairment of assets			58,210
Acquisition-related expenses (income), net		(13,454)		(6,566)
Loss from equity method investments	1,420	1,837	4,495	1,837
Operating loss	(32,772)	(23,785)	(179,842)	(85,190)
Foreign exchange (gain) loss, net	(9,319)	2,585	5,424	1,153
Change in fair value of warrant liability	(31,913)		51,275
Interest expenses, net	10,437	8,680	30,147	26,005
Finance income from ABG		(210)		(557)
Other expense (income), net	(38)	(1,116)	4,944	(6,185)
Loss before income taxes	(1,939)	(33,724)	(271,632)	(105,606)
Deferred income tax expenses (recoveries)	134	2,432	(4,013)	(3,987)
Current income tax expenses (benefit)	243	195	505	402
Net loss	$ (2,316)	$ (36,351)	$ (268,124)	$ (102,021)
Net loss per share - basic and diluted	$ (0.02)	$ (0.37)	$ (2.23)	$ (1.05)
Weighted average shares used in computation of net loss per share - basic and diluted	129,100,909	98,130,507	120,128,856	96,742,626
Net loss	$ (2,316)	$ (36,351)	$ (268,124)	$ (102,021)
Foreign currency translation gain (loss), net	2,265	(4,863)	(7,184)	(2,414)
Unrealized gain on available-for-sale debt securities	193	11	154	80
Other comprehensive income (loss)	2,458	(4,852)	(7,030)	(2,334)
Comprehensive income (loss)	142	(41,203)	(275,154)	(104,355)
Product Costs [Member]
Cost of sales	34,224	35,047	108,616	85,806
Inventory Valuation Adjustments [Member]
Cost of sales	$ 13,443	$ 201	$ 36,116	$ 726

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	ABG [Member]	Natura Naturals Inc [Member]	Manitoba Harvest US LLC [Member]	Investments and S&S [Member]	Common Stock [Member]	Common Stock [Member]ABG [Member]	Common Stock [Member]Natura Naturals Inc [Member]	Common Stock [Member]Manitoba Harvest US LLC [Member]	Common Stock [Member]Investments and S&S [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]ABG [Member]	Additional Paid-In Capital [Member]Natura Naturals Inc [Member]	Additional Paid-In Capital [Member]Manitoba Harvest US LLC [Member]	Additional Paid-In Capital [Member]Investments and S&S [Member]	Accumulated Other Comprehensive (loss) Income [Member]	Accumulated Other Comprehensive (loss) Income [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Deficit [Member]ABG [Member]
Beginning Balance at Dec. 31, 2018	$ 197,653						$ 10					$ 302,057					$ 3,763		$ (108,177)
Beginning Balance (ASU 2016-01 [Member]) at Dec. 31, 2018																		$ 803		$ (803)
Beginning Balance (ASC 842 [Member]) at Dec. 31, 2018		$ 19																		19
Beginning Balance, Shares at Dec. 31, 2018							93,170,867
Shares issued for acquisition			$ 125,097	$ 15,100	$ 96,844								$ 125,097	$ 15,100	$ 96,844
Shares issued for acquisition, shares								1,680,214	180,332	1,209,946
ABG finance receivable, net of finance income	(30,292)											(30,292)
Shares issued under stock-based compensation plans	931											931
Shares issued under stock-based compensation plans, shares							545,000
Shares issued for employee compensation	649											649
Shares issued for employee compensation, shares							11,868
Stock-based compensation expenses	5,736											5,736
Other comprehensive (loss) income	(456)																(456)
Net loss	(29,369)																		(29,369)
Ending Balance at Mar. 31, 2019	381,912						$ 10					516,122					4,110		(138,330)
Ending Balance, Shares at Mar. 31, 2019							96,798,227
Beginning Balance at Dec. 31, 2018	197,653						$ 10					302,057					3,763		(108,177)
Beginning Balance (ASU 2016-01 [Member]) at Dec. 31, 2018																		$ 803		(803)
Beginning Balance (ASC 842 [Member]) at Dec. 31, 2018		$ 19																		$ 19
Beginning Balance, Shares at Dec. 31, 2018							93,170,867
Other comprehensive (loss) income	(2,334)
Net loss	(102,021)
Ending Balance at Sep. 30, 2019	415,611						$ 10					624,351					2,232		(210,982)
Ending Balance, Shares at Sep. 30, 2019							100,271,743
Beginning Balance at Mar. 31, 2019	381,912						$ 10					516,122					4,110		(138,330)
Beginning Balance, Shares at Mar. 31, 2019							96,798,227
Shares issued for acquisition	70											70
Shares issued for acquisition, shares							28,361
Shares issued under stock-based compensation plans	3,483											3,483
Shares issued under stock-based compensation plans, shares							530,943
Stock-based compensation expenses	7,923											7,923
Other comprehensive (loss) income	2,974																2,974
Net loss	(36,301)																		(36,301)
Ending Balance at Jun. 30, 2019	360,061						$ 10					527,598					7,084		(174,631)
Ending Balance, Shares at Jun. 30, 2019							97,357,531
Shares issued for common stock at-the-market, net of issuance costs	37,445											37,445
Shares issued for common stock at-the-market, net of issuance costs, shares							1,344,166
Shares issued for acquisition					$ 31,866	$ 14,438									$ 31,866	$ 14,438
Shares issued for acquisition, shares										899,306	433,338
Finance income for receivable for ABG Profit Participation Arrangement	1,393											1,393
Shares issued under stock-based compensation plans	2,967											2,967
Shares issued under stock-based compensation plans, shares							237,402
Stock-based compensation expenses	8,644											8,644
Other comprehensive (loss) income	(4,852)																(4,852)
Net loss	(36,351)																		(36,351)
Ending Balance at Sep. 30, 2019	415,611						$ 10					624,351					2,232		(210,982)
Ending Balance, Shares at Sep. 30, 2019							100,271,743
Beginning Balance at Dec. 31, 2019	285,271						$ 11					705,671					9,719		(430,130)
Beginning Balance, Shares at Dec. 31, 2019							102,781,225
Proceeds from ABG Profit Participation Arrangement			$ 1,353										1,353
Write-off of ABG finance receivable													$ 28,900								$ (28,900)
Escrow shares released from downstream merger	(151)											(151)
Escrow shares released shares from downstream merger, shares							(7,659)
Shares issued for common stock at-the-market, net of issuance costs	27,027											27,027
Shares issued for common stock at-the-market, net of issuance costs, shares							2,265,115
Shares issued for acquisition, shares							6,934
Shares issued under stock-based compensation plans	1,079											1,079
Shares issued under stock-based compensation plans, shares							597,868
Stock-based compensation expenses	7,677											7,677
Shares issued under registered offering, net of issuance costs	19,828						$ 1					19,827
Shares issued under registered offering, net of issuance costs, Shares							7,250,000
Shares issued for exercise of pre-funded warrants	49,054						$ 1					49,053
Shares issued for exercise of pre-funded warrants. Shares							11,750,000
Other comprehensive (loss) income	(16,707)																(16,707)
Net loss	(184,123)																		(184,123)
Ending Balance at Mar. 31, 2020	190,308						$ 13					840,436					(6,988)		(643,153)
Ending Balance, Shares at Mar. 31, 2020							124,643,483
Beginning Balance at Dec. 31, 2019	285,271						$ 11					705,671					9,719		(430,130)
Beginning Balance, Shares at Dec. 31, 2019							102,781,225
Other comprehensive (loss) income	(7,030)
Net loss	(268,124)
Ending Balance at Sep. 30, 2020	186,717						$ 13					911,171					2,689		(727,156)
Ending Balance, Shares at Sep. 30, 2020							133,289,944
Beginning Balance at Mar. 31, 2020	190,308						$ 13					840,436					(6,988)		(643,153)
Beginning Balance, Shares at Mar. 31, 2020							124,643,483
Escrow shares released from downstream merger	(378)											(378)
Escrow shares released shares from downstream merger, shares							(42,785)
Shares issued for common stock at-the-market, net of issuance costs	3,842											3,842
Shares issued for common stock at-the-market, net of issuance costs, shares							447,289
Shares issued under stock-based compensation plans	4,536											4,536
Shares issued under stock-based compensation plans, shares							883,425
Stock-based compensation expenses	7,647											7,647
Other comprehensive (loss) income	7,219																7,219
Net loss	(81,687)																		(81,687)
Ending Balance at Jun. 30, 2020	131,487						$ 13					856,083					231		(724,840)
Ending Balance, Shares at Jun. 30, 2020							125,931,412
Shares issued for common stock at-the-market, net of issuance costs	45,230											45,230
Shares issued for common stock at-the-market, net of issuance costs, shares							6,781,090
Shares issued for acquisition	1,492											1,492
Shares issued for acquisition, shares							202,224
Shares issued under stock-based compensation plans	286											286
Shares issued under stock-based compensation plans, shares							375,218
Stock-based compensation expenses	8,080											8,080
Other comprehensive (loss) income	2,458																2,458
Net loss	(2,316)																		(2,316)
Ending Balance at Sep. 30, 2020	$ 186,717						$ 13					$ 911,171					$ 2,689		$ (727,156)
Ending Balance, Shares at Sep. 30, 2020							133,289,944

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
ABG [Member]
Finance income	$ 2,700

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (268,124)	$ (102,021)
Adjusted for the following items:
Inventory valuation adjustments	36,116
Depreciation and amortization expenses	14,232	10,460
Impairment of assets	58,210
Stock-based compensation expenses	23,404	22,303
Change in fair value of warrant liability	51,275
Loss from equity method investments	4,495	1,837
Change in fair value of contingent consideration		(17,019)
Loss from equity investments measured at fair value	1,272	1,572
Loss from sale of investment	65
Interest on debt securities	(601)
Deferred taxes	(4,013)	(3,987)
Amortization of discount on convertible notes	7,944	7,616
Amortization of transaction costs on Senior Facility	943
Foreign currency loss	5,424
Accretion related to obligations under finance leases	394	138
Issuance costs on registered offering recorded to net loss	3,953
Credit loss expenses	288	520
Provision for sales returns	(188)
Loss on disposal of property and equipment	885	112
Other non-cash items	88	1,755
Changes in non-cash working capital:
Accounts receivable	11,072	(15,019)
Inventory	(25,476)	(73,758)
Prepayments and other current assets	4,263	(54,607)
Accounts payable	(12,544)	38,773
Accrued expenses and other current liabilities	(17,863)	16,539
Net cash used in operating activities	(104,486)	(167,255)
Investing activities
Business combinations, net of cash acquired		(166,086)
Interest receipts on debt securities	146
Investment in joint venture with AB InBev	(2,323)
Change in deposits and other assets	(3,148)	85
Purchases of short-term and other investments		(8,486)
Proceeds from the sale of other investments	437	8,640
Purchases of property and equipment	(39,366)	(50,421)
Proceeds from disposal of property and equipment	2,371
Purchases of intangible assets		(941)
Net cash used in investing activities	(41,883)	(264,844)
Financing activities
Proceeds from at-the-market equity offering, net of costs	75,459	37,445
Proceeds from ABG Profit Participation Arrangement	1,353	3,333
Proceeds from issuance of registered offering, net of issuance costs	85,465
Payment of ABG finance liability	(1,500)
Proceeds from exercise of stock options	6,007	4,885
Payment of obligations under finance lease	(309)	(565)
Payment on the settlement of stock options	(1,144)
Proceeds from issuance of Senior Facility, net of transaction costs	46,395
Repayment of Senior Facility	(1,605)
Net cash provided by financing activities	210,121	45,098
Effect of foreign currency translation on cash and cash equivalents	(5,338)	(95)
Increase (decrease) in cash and cash equivalents	58,414	(387,096)
Cash and cash equivalents, beginning of period	96,791	487,255
Cash and cash equivalents, end of period	$ 155,205	100,159
Investment In ABG [Member]
Investing activities
Investment in ABG Profit Participation Arrangement		(33,333)
S & S Acquisition [Member]
Investing activities
Investment in equity method investees and S&S acquisition		$ (14,302)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Description of the business Tilray, Inc. and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, “our”, or “us”) is a global medical cannabis research, cultivation, processing and distribution organization, and is one of the leading suppliers of adult-use cannabis in Canada. The Company also markets and distributes food products from hemp seed and offers a broad range of natural and organic hemp based food products and ingredients that are sold through retailers and websites globally. Basis of presentation and going concern The accompanying unaudited condensed consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. These financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due. For the three and nine months ended September 30, 2020, the Company reported a consolidated net loss of $2,316 and $268,124, and a net loss of $36,351 and $102,021 for the three and nine months ending September 30, 2019. For the nine months ended September 30, 2020, the Company had cash flows used in operating activities of $104,486 and cash flows used in operating activities of $167,255 for the nine months ended September 30, 2019. As at September 30, 2020 and December 31, 2019 the Company had working capital of $171,349 and $166,600, respectively. Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the current cash on hand for the next twelve months from the date of issuance of these financial statements. On March 17, 2020, the Company received net proceeds of $85,289 ($90,439 of gross proceeds) from its registered equity offering (refer to Note 14). 19,000,000 warrants were issued as part of the offering. All the warrants remain outstanding as of September 30, 2020. The warrants issued contain an anti-dilution provision that was approved by a vote of the Company’s stockholders at its Annual Meeting held on May 28, 2020. While the Company has the ability to issue securities under its at-the-market program, because warrants from the equity offering remain outstanding as of September 30, 2020, the Company may only issue up to $20,000 in aggregate gross proceeds under its at-the-market offering program at prices less than the exercise price of the warrants (currently $5.95 per share), and in no event more than $6,000 per quarter at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection feature. During the three months ended September 30, 2020, the Company received gross proceeds of $46,153 from shares sold under its at-the-market offering program. All shares were sold at share prices above $5.95 per share. On February 28, 2020, the Company completed a debt financing under its Senior Facility with maximum aggregate principal amount of $59,600 and borrowed an aggregate principal amount of $49,700. The Senior Facility provided for an additional draw of $9,900. On June 5, 2020, as a result of COVID-19 related financial markets conditions that affected the lender and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that Tilray withdraw its then outstanding request for the additional draw of $9,900 and entered into an amendment to its Senior Facility which provides for, among other things, interest-only payments for the remainder of its term with all outstanding principal payments due at February 28, 2022 (refer to Note 13). As of September 30, 2020, the Company had cash and cash equivalents of $155,205. During the last nine months management has implemented a series of cost reduction strategies including headcount reductions and the closure of certain facilities. Currently, management’s forecasts and related assumptions indicate that the Company will remain in compliance with all its debt covenants and, over the next twelve months from the date of issuance of these financial statements, will be able to satisfy all its contractual obligations such as payment of interest on the 5% convertible notes (refer to Note 12 and Note 18), interest-only payments on the Senior Facility (refer to Note 13 and Note 18), non-cancelable minimum purchase commitments for inventory (refer to Note 18), payment of the ABG finance liability (refer to Note 18), payment of the Company’s lease commitments (refer to Note 18) and payment of the Company’s Portugal construction commitments (refer to Note 18). Due to uncertainties the Company may face in raising additional equity financing in the future, which may be further impacted by the economic downturn and unprecedented conditions due to COVID-19, there remains uncertainty about the impact this may have on management ’ s assumptions used to develop these forecasts. Accordingly, the Company has concluded it is probable that it can implement plans that would effectively mitigate the conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern for the next twelve months. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to successfully implement its initiatives. Any such adjustments could be material. Changes in comparative presentation The Company lost its emerging growth company status effective December 31, 2019 and therefore reported as a large accelerated filer in the Annual Financial Statements. As a result, the Company complies with new and revised accounting standards applicable to public companies. In the fourth quarter of 2019, the Company adopted the following accounting pronouncements issued by FASB: ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”); ASU 2016-02, Leases, codified as ASC 842 (“ASC 842”); ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU, codified as ASC 606 (“ASC 606”); and ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), as described in the Annual Financial Statements, with an effective date of January 1, 2019. The comparative three and nine months ended September 30, 2019 included in the financial statements reflect the new and revised accounting standards and therefore does not mirror the September 30, 2019 interim period condensed consolidated financial statements previously filed. The impact to the statements of net loss and comprehensive loss for the three and nine months ended September 30, 2019 is as follows: Three months ended September 30, 2019 Nine months ended September 30, 2019 Net loss Other comprehensive (loss) income Net (loss) income Other comprehensive (loss) income Unadjusted $ (35,678 ) $ (5,164 ) $ (101,032 ) $ (2,069 ) Impact of adoption of accounting standards: ASU 2016-01 (312 ) 312 265 (265 ) ASC 842 (32 ) — (157 ) — ASU 2018-07 (329 ) — (1,097 ) — ASC 606 — — — — Adjusted $ (36,351 ) $ (4,852 ) $ (102,021 ) $ (2,334 ) The statement of net loss and comprehensive loss for the three and nine months ended September 30, 2019 was reclassified to conform to the current period’s presentation. In addition, unrelated to the impact of adoption of accounting standards, cost of sales, which was formerly presented as a single line item, is separated between product costs and inventory valuation adjustments. Loss on disposal of property and equipment, formerly presented in other expenses (income) is now presented in general and administrative expenses. Assets held for sale In May 2020, the Company announced its decision to close the High Park Gardens facility in response to its anticipated future product needs and the current economic climate. As a result, the Company adopted an accounting policy for assets held for sale. Assets held for sale are accounted for in accordance with applicable accounting guidance provided in ASC Topic 360, Property, Plant and Equipment. The Company classifies its assets as held for sale if, among other criteria, the carrying amount will be recovered principally through a sale transaction rather than continued use and a sale is considered probable and within one year. Assets classified as held for sale are measured at the lower of the carrying amount and fair value less costs to sell. An impairment loss is recognized in impairment of assets through the statements of net loss and comprehensive loss for any initial or subsequent write-down of the asset to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset, but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the asset is recognized at the date of derecognition. Assets are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities classified as held for sale continue to be recognized. Assets classified as held for sale are combined and presented separately from the other assets in the balance sheets. Allowance for credit losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This guidance was subsequently amended by ASU 2018-19, Codification Improvements, ASU 2019- 04, Codification Improvements, ASU 2019-05, Targeted Transition Relief, ASU 2019-10, Effective Dates, and ASU 2019-11, Codification Improvements. These ASUs are referred to collectively as the new guidance on current expected credit loss (“CECL”). As a result of the adoption of the new CECL guidance on January 1, 2020, the Company has changed its accounting policy for the allowance for credit losses, as it relates to accounts receivable and available-for-sale debt securities. The adoption of the CECL guidance did not have a material impact on the consolidated financial statements at January 1, 2020. Accounts receivable – The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses. The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classes and the expected future loss. This assessment incorporates all available information relevant to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts. As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class. Available-for-sale debt securities Disclosure framework - fair value measurement In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) (“ASU 2018-13”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC Topic 820, (b) the policy for timing of transfers between levels, and (c) the valuation process used for Level 3 fair value measurements. ASU 2018-13 also adds, among other items, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The Company adopted ASU 2018-13 effective January 1, 2020 and such adoption did not have a material effect on its financial statements. Warrants In March 2020, the Company closed on a registered offering including Class 2 common stock, warrants, and pre-funded warrants (refer to Note 14). Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company's warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each balance sheet date until settlement and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of net loss and comprehensive loss. Transaction costs allocated to warrants that are presented as a liability are expensed immediately within other expenses (income) in the statements of net loss and comprehensive loss. Use of estimates and significant judgements Assets held for sale – The Company uses a third party real estate agent to assist management in its determination of the fair value of the assets held for sale. The Company estimates the fair value by reviewing market data from recent sales of similar properties and determining an implied sale price per acre of land and greenhouse space. Allowance for credit losses – The Company’s projections of expected credit losses are inherently uncertain, and as a result the Company cannot predict with certainty the amount of such losses. Changes in economic conditions, the risk characteristics and composition of the portfolio, bankruptcy laws, and other factors could impact the actual and projected expected credit losses and the related allowance for credit losses. Actual losses may vary from current estimates. Due to potential COVID-19 disruptions in the marketplace it is possible the Company may experience unforeseen and greater credit losses than anticipated or experienced historically. Warrant liability – The Company estimates the fair value of the warrant liability using a Monte Carlo pricing model. The Company is required to make assumptions and estimates in determining an appropriate risk-free interest rate, volatility, term, dividend yield and discount due to exercise restrictions and fair value of common stock. Net loss per share Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential additional dilutive common share equivalents consist of warrants, stock options, restricted stock units (“RSUs”) and restricted stock awards. In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. As of September 30, 2020, there were 13,141,298 common share equivalents with potential dilutive impact (September 30, 2019 – 8,043,920). Because the Company is in a net loss for all periods presented in these financial statements, there is no difference between the Company’s basic and diluted net loss per share for the periods presented. New accounting pronouncements not yet adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU. In January 2020, the FASB issued ASU 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying generally accepted accounting principles (GAAP) for certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 is effective for the Company beginning January 1, 2022. The Company is currently evaluating the effect of adopting this ASU.

Assets Held for Sale

Assets Held for Sale	9 Months Ended
	Sep. 30, 2020
Assets Of Disposal Group Including Discontinued Operation [Abstract]
Assets Held for Sale	2. Assets held for sale On May 26, 2020, the Company announced its decision to close its High Park Gardens facility, a wholly-owned subsidiary of the Company based in Leamington, Ontario in response to its anticipated future product needs and the current economic climate. The Company concluded that the assets attributable to High Park Gardens, which are expected to be sold to a third-party within twelve months, met the criteria for classification as assets held for sale as of September 30, 2020. As a result of the Company’s decision to close this facility, the Company recognized impairment charges of $25,051 recorded to impairment of assets within the statements of net loss and comprehensive loss to adjust the fair value, less costs to sell, of the assets classified as held for sale. This included impairment charges of $13,616 relating to land and buildings (refer to Note 8), $10,239 relating to the write-down to nil of its cultivation license (refer to Note 10) and $1,196 relating to foreign currency translation adjustments. The disposal group is included in the Company’s cannabis segment. The carrying amount of major classes of assets comprising the disposal group classified as held for sale are as follows: As of September 30, 2020 Assets classified as held for sale Land and buildings $ 6,797 Cultivation license — Total assets held for sale $ 6,797 The following table provides summary pretax (loss) income for the High Park Gardens facility, which are included in continuing operations for their respective periods: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Pre-tax (loss) income $ (642 ) $ 119 $ (28,335 ) $ (396 ) Pretax loss for the nine months ended September 30, 2020 includes impairment charges of $25,051.

ABG Profit Participation Arrang

ABG Profit Participation Arrangement	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
ABG Profit Participation Arrangement	3 . ABG Profit Participation Arrangement The Company entered into a Profit Participation Arrangement (“ABG Arrangement”) with ABG Intermediate Holdings 2, LLC (“ABG”) on January 14, 2019 as described in the . On January 24, 2020, the Company entered into (i) an Amended and Restated Profit Participation Agreement (the “A&R Profit Participation Agreement”) with ABG, which amended and restated in its entirety the Profit Participation Agreement, dated January 14, 2019, and (ii) the First Amendment to Payment Agreement with ABG (the “Payment Agreement Amendment”), which amends the Payment Agreement, dated January 14, 2019. The Company and ABG agreed that Tilray no longer has any obligation to pay the additional consideration with an aggregate value of $83,333 in cash or in shares of Class 2 common stock. In addition, the Company is not entitled to any guaranteed minimum participation rights and beginning January 1, 2020 through December 31, 2028, the Company agreed that it is not entitled to any participation rights until such participation rights with respect to each contract year exceeds $10,000, and in the event the participation rights thresholds are achieved, the Company is entitled to the full 49% participation rights. As a result of entering into the A&R Profit Participation Agreement and the Payment Agreement Amendment, the Company derecognized the ABG finance receivable, $7,011 of which was recorded to impairment of assets through the statements of net loss and comprehensive loss and $28,900 of which was recorded through accumulated deficit in January 2020. The Company entered into a Trademark License Agreement with ABG on April 1, 2019 for the use of the Prince trademark (“ABG Prince Agreement”). Under the ABG Prince Agreement, the Company pays a royalty on actual product sales in addition to a guaranteed minimum royalty payment (“GMR”) of $500 on April 1, 2019, October 1, 2019, January 1, 2020 and July 1, 2020, with subsequent quarterly payments of $375 commencing January 1, 2021 until the maturity date of December 31, 2025.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventory	4 . Inventory Inventory is comprised of the following items: September 30, 2020 December 31, 2019 Raw materials $ 15,338 $ 15,926 Work-in-process 59,863 53,973 Finished goods 14,716 17,962 Total $ 89,917 $ 87,861 Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Raw materials $ 173 $ — $ 384 $ — Work-in-process 11,164 201 30,656 726 Finished goods 2,106 — 5,076 — Total $ 13,443 $ 201 $ 36,116 $ 726 For the three and nine months ended September 30, 2020, cannabis products were written down by $13,318 and $31,626 (2019 – $124 and $610) and hemp products were written down by $125 and $4,490 (2019 – $77 and $116). In the three and nine months ended September 30, 2020, included in inventory valuation adjustments in cost of sales, $5,157 and $10,090 related to termination of a supply agreement; $4,934

Prepayments and Other Current A

Prepayments and Other Current Assets	9 Months Ended
	Sep. 30, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepayments and Other Current Assets	5 . Prepayments and Other Current Assets Prepayments and other current assets are comprised of the following items: September 30, 2020 December 31, 2019 Deposits $ 15,325 $ 25,490 Prepayments 6,854 5,847 Taxes receivable 5,975 6,165 ABG finance receivable - current — 671 Total $ 28,154 $ 38,173 Deposits include advance payments on future purchases of inventory to secure supply. During the nine months ended September 30, 2020, the Company reached agreement with certain suppliers to terminate supply agreements. As a result, deposits have been written down by $4,934 in the Cannabis segment and were recorded in inventory valuation adjustments in the statements of net loss and comprehensive loss (refer to Note 4).

Investments

Investments	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Investments	6 . Investments Other investments Long-term investments are comprised of the following items: September 30, 2020 December 31, 2019 Equity investments at fair value $ 2,207 $ 4,183 Equity investments under measurement alternative 14,738 14,954 Debt securities classified under available-for-sale method 5,765 5,047 Total other investments $ 22,710 $ 24,184 Unrealized gains and losses recognized in other expense (income) during the three and nine months ended September 30, 2020 on equity investments still held at September 30, 2020 are losses of $506 and $1,272 (2019 – loss of $274 and gain of $264). There were no impairments or adjustments to equity investments under the measurement alternative for the three and nine months ended September 30, 2020 and September 30, 2019. The Company’s debt securities accounted for under the available-for-sale method consist of convertible debt instruments with contractual maturities in 2022. Total unrealized loss of $148 in accumulated other comprehensive income at September 30, 2020 (December 31, 2019 - $302) relates to the long-term available-for-sale debt securities. The Company’s allowance for credit losses on debt securities classified as available-for-sale is $0 at September 30, 2020 (December 31, 2019 – $0) and no related credit loss expenses were recorded during the three and nine months ended September 30, 2020 (2019 – $0 and $0). Equity method investments Equity method investments are comprised of the Company’s joint venture with Anheuser-Busch InBev (“AB InBev”) in Plain Vanilla Research Limited Partnership (“Fluent”) and the Company’s joint venture with Cannfections Group Inc. (“Cannfections”). As of September 30, 2020, there are no changes to the status of the Company’s assessment of its joint ventures. During the nine months ended September 30, 2020, the Company contributed $2,323 to Fluent (2019 - $10,090). The Company provides production support services to Fluent on a cost recovery basis. For the nine months ended September 30, 2020, total fees charged were $3,109 (2019 - $0). Total amounts included in accounts payable is $441 at September 30, 2020 (December 31, 2019 – accounts receivable of $388). At September 30, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Fluent. During the nine months ended September 30, 2020, the Company made no capital contributions to Cannfections (2019 - $3,600). At September 30, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Cannfections. The Company’s ownership interests in its equity method investments as of September 30, 2020 and December 31, 2019 and (loss) gain from equity method investments for the nine months ended September 30, 2020 were as follows: Approximate Carrying value (Loss) gain from equity method investments for the nine months ended ownership % September 30, 2020 September 30, 2020 Investment in Fluent 50% $ 5,147 $ (4,725 ) Investment in Cannfections 50% 3,764 230 Total equity method investments $ 8,911 $ (4,495 ) Approximate Carrying value (Loss) gain from equity method investments for the nine months ended ownership % December 31, 2019 September 30, 2019 Investment in Fluent 50% $ 7,836 $ (1,837 ) Investment in Cannfections 50% 3,612 — Total equity method investments $ 11,448 $ (1,837 ) Summary financial information for the Company’s equity method investments on an aggregate basis is as follows: September 30, 2020 December 31, 2019 Current assets $ 12,346 $ 13,942 Noncurrent assets $ 5,205 $ 4,987 Current liabilities $ 4,965 $ 1,561 Noncurrent liabilities $ — $ — Nine months ended September 30, 2020 2019 Revenue $ 4,854 $ — Gross profit $ 2,032 $ — Net loss $ (8,991 ) $ (3,160 )

Allowance for Credit Losses

Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2020
Allowance For Credit Loss [Abstract]
Allowance for Credit Losses	7. Allowance for Credit Losses Accounts receivable The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in the existing accounts receivable portfolio as of the reporting dates based on the estimate of expected net credit losses. The following table provides activity in the allowance for credit losses for the nine months ended September 30, 2020: Allowance for credit losses, January 1, 2020 $ 615 Provision for expected credit losses (1) 288 Write-offs charged against allowance (74 ) Recoveries of amounts previously written off — Foreign currency translation adjustment (3 ) Allowance for credit losses, September 30, 2020 $ 826 Accounts receivable balance before allowance for credit losses and provision for sales returns, September 30, 2020 $ 26,843 (1) The provision for expected credit losses is recorded in general and administrative expenses. Available-for-sale debt securities The Company holds investments in two available-for-sale debt securities, one of which is in an unrealized loss position. The unrealized loss relates to an investment in the convertible debentures of a recreational cannabis company. This investment is deemed not to have a credit loss. The unrealized loss primarily reflects an extended period of general volatility in the cannabis industry, as well as the more recent volatility in the overall economy due to COVID-19. The Company expects to recover the entire amortized cost basis of the security. The Company does not intend to sell the investment and it is not more likely than not that the Company will be required to sell the investment before recovery of its amortized cost basis. The following table provides the fair value and unrealized loss of the investment at September 30 , 2020 and December 31, 2019: September 30, 2020 December 31, 2019 Fair value $ 1,124 $ 945 Unrealized loss $ 148 $ 302

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, Net	8 . Property and Equipment, Net Property and equipment, net consists of the following: September 30, 2020 December 31, 2019 Land $ 6,488 $ 6,417 Buildings and leasehold improvements 108,021 109,172 Laboratory and manufacturing equipment 34,500 31,173 Office and computer equipment 1,779 2,659 Right-of-use assets under finance lease 14,415 14,753 Construction-in-process, not yet available for use 46,551 37,160 211,754 201,334 Less: accumulated depreciation (24,124 ) (17,117 ) Total $ 187,630 $ 184,217 In connection with the Company’s closure of its High Park Gardens facility, the Company determined that the fair value of the land and buildings at the High Park Gardens facility (Level 2) was below its carrying value. The decline in fair value of the land and buildings at the High Park Gardens facility is primarily due to recent sales of similar properties resulting in a lower implied sale price per acre of land and greenhouse space. As a result, the Company incurred non-cash impairment charges of $13,616 presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 2). Refer to Note 18 for contractual commitments related to construction-in-process.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2020
Goodwill Disclosure [Abstract]
Goodwill	9 . Goodwill The following table shows the change in carrying amount of goodwill: Hemp Cannabis Total Balance as of December 31, 2019 $ 133,314 $ 29,937 $ 163,251 Foreign currency translation adjustment (2,971 ) (685 ) (3,656 ) Balance as of September 30, 2020 $ 130,343 $ 29,252 $ 159,595 Goodwill is tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. At the end of the first quarter of 2020, the Company determined the hemp reporting unit, representing $130,343 of the $159,595 total goodwill, was at risk of having a carrying value exceeding the fair value. As a result, a quantitative test was performed to determine if impairment exists. In performing the Company’s impairment analysis, the fair value of the hemp reporting unit was determined primarily by discounting estimated future cash flows, which were determined based on revenue and expense growth assumptions ranging from 9% to 38%, at a weighted average cost of capital (discount rate) ranging from 10% to 12%. The discounted future cash flow model also made the key assumption that Cannabidiol (“CBD”) revenue will commence to build in the third quarter of 2021. The fair value of the hemp reporting unit was determined to exceed the carrying value by $76,998, or 26%, and no impairment was recorded. No triggers have been identified in subsequent quarters to perform additional quantitative tests. A relatively small change in the underlying assumptions, including a 1% change in the weighted average cost of capital, continued lack of clarity from the Food and Drug Administration regarding approval of CBD, or the financial performance of the reporting unit in future years, may cause a change in the results of the impairment assessment in future periods and, as such, could result in an impairment of goodwill.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2020
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	10 . Intangible Assets Intangible assets are comprised of the following items: September 30, December 31, 2020 2019 Cost Accumulated Amortization Impairment Net Cost Accumulated Amortization Impairment Net Definite-lived intangible assets: Patent $ 669 $ 131 $ 538 $ — $ 716 $ 99 $ — $ 617 Customer relationships 132,837 13,241 — 119,596 135,953 7,132 — 128,821 Developed technology 6,912 1,094 — 5,818 7,074 590 — 6,484 Websites 5,126 3,921 — 1,205 5,157 3,331 — 1,826 Trademarks and licenses 9,052 1,293 7,650 109 9,135 925 — 8,210 Total 154,596 19,680 8,188 126,728 158,035 12,077 — 145,958 Indefinite-lived intangible assets: Cultivation license 10,239 — 10,239 — 10,689 — — 10,689 Alef license — — — — 4,086 — 4,086 — Trademarks 54,125 — — 54,125 55,416 — — 55,416 Rights under ABG Profit Participation Arrangement 16,765 — 16,765 — 119,366 — 102,601 16,765 Total 81,129 — 27,004 54,125 189,557 — 106,687 82,870 Total intangible assets 235,725 19,680 35,192 180,853 $ 347,592 $ 12,077 $ 106,687 $ 228,828 In connection with the Company’s closure of its High Park Gardens facility, the Company determined that the fair value of the indefinite-lived cultivation license was below carrying value. As a result, the Company incurred non-cash impairment charges of $10,239, representing the full net book value of the cultivation license, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 2). In connection with the decreased demand projections of CBD products in the United States resulting in a reduced estimate of future cash flows, during the first quarter of 2020 the Company determined that the fair value of indefinite-lived rights under the ABG Profit Participation Arrangement and definite-lived trademarks under the Trademark and License Agreement with ABG for the use of the Prince trademark (“ABG Prince Agreement”) were below the carrying value. As a result, the Company incurred non-cash impairment charges of $16,765 and $6,063 representing the full net book values of the intangible assets relating to the ABG Profit Participation Agreement and ABG Prince Agreement respectively, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 3). In June 2020, the Company completed the separation from Smith & Sinclair and recognized additional non-cash impairment charges of $3,320 presented in impairment of assets in the statement of net loss and comprehensive loss, of which $2,126 related to other CBD trademarks and patents. Amortization expenses for intangibles was $2,765 and $7,603 for the three and nine months ended September 30, 2020 (2019 – $2,529 and $6,131). Expected future amortization expenses for intangible assets as at September 30, 2020 are as follows: Year ending December 31, Amortization 2020 (remaining three months) $ 2,522 2021 9,801 2022 9,306 2023 9,078 2024 9,078 Thereafter 86,943 Total $ 126,728

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2020
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	1 1 . Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following items: September 30, 2020 December 31, 2019 Accrued interest on convertible notes $ 11,875 $ 5,938 Accrued payroll and employment related withholding taxes 10,709 24,765 Other accrued expenses and current liabilities 8,031 17,032 ABG finance liability - current 1,125 1,500 Accrued interest on Senior Facility 422 — Accrued legal and professional fees 364 1,174 Contingent consideration for acquisitions — 420 Total accrued expenses and other current liabilities $ 32,526 $ 50,829 During the nine months ended September 30, 2020, the Company reduced its employee headcount in portions of its global organization to meet the needs of the current industry environment. During the three and nine months ended September 30, 2020, the Company incurred $239 and $3,576, respectively (2019 – $0 and $0), in severance costs, of which $133 and $3,128 is included in salaries within general and administrative expenses and $106 and $448 is included in cost of sales. During the three and nine months ended September 30, 2020, severance costs of $239 and $2,432 are allocated to the cannabis reportable segment and $0 and $1,144 are allocated to the hemp reportable segment. Management continues to evaluate its cost structure and may take further actions in the future and incur additional related costs. The following table shows the reconciliation of the severance costs included within the accrued payroll and employment related withholding taxes balance above, relating to scheduled benefit payments which were communicated to employees prior to September 30, 2020: Opening Balance as of January 1, 2020 $ — Additional charges 3,575 Less payments made to employees (3,393 ) Closing Balance as of September 30, 2020 $ 182

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Notes	1 2 . Convertible Notes The Company has convertible senior notes with a face value of $475,000. As of September 30, 2020, the convertible notes are not yet convertible and the Company is in compliance with all covenants. The following table sets forth the net carrying amount of the convertible notes: September 30, 2020 December 31, 2019 5.00% Convertible Notes $ 475,000 $ 475,000 Unamortized discount (28,133 ) (34,219 ) Unamortized transaction costs (8,713 ) (10,571 ) Net carrying amount $ 438,154 $ 430,210 The following table sets forth total interest expense recognized related to the convertible notes: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Contractual coupon interest $ 5,938 $ 5,938 $ 17,813 $ 17,813 Amortization of discount 2,059 1,969 6,087 5,790 Amortization of transaction costs 641 614 1,857 1,826 Total $ 8,638 $ 8,521 $ 25,757 $ 25,429

Senior Facility

Senior Facility	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Senior Facility	1 3 . On February 28, 2020, High Park Holdings Ltd., a wholly owned subsidiary of the Company (the “Borrower”) entered into a credit agreement, denominated in Canadian dollars (“C$”), for a senior secured credit facility in a maximum aggregate principal amount of $59,600 (C$79,800) (the “Senior Facility”). An aggregate principal amount equal to $49,700 (C$66,500) was drawn on February 28, 2020 (the “Closing Date Draw”) and the Company submitted an irrevocable 30 day notice on May 4, 2020 to draw an additional $9,900 (C$13,300) (the “Additional Draw”). On June 5, 2020, a s a result of COVID-19 related financial markets conditions that affected the lender of the Senior Facility, and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that Tilray withdraw its outstanding request for the Additional Draw of $9,900 (C$13,300) under the Senior Facility. In exchange for the Company’s accommodation of the lender’s request to withdraw its funding request, the lender agreed to enter into the First Amendment of the Senior Facility (the “Amendment”). The Amendment provides for interest-only payments for the remainder of its term with all outstanding principal payments due at February 28, 2022. This will result in an aggregate balance of $47,355 (C$64,283) due at February 28, 2022. Additionally, and at such time as the lender’s business may allow, the lender may make the additional proceeds of $9,900 (C$13,300) available, at its sole discretion. Concurrently, with the Amendment, the lender also approved the Company’s ability to sell the High Park Gardens facility, which is classified as assets held for sale (refer to Note 2), if and when Tilray so desires. As part of any sale of the High Park Gardens facility, the lender has agreed that the Company may retain 60% of any sales proceeds (net of all expenses, fees and taxes), and that the lender will receive 40% of all sales proceeds (net of all expenses, fees and taxes). All sales proceeds to the lender will be applied as a repayment of principal on the Senior Facility without any prepayment penalties or fees. The sale of the High Park Gardens facility is expected to be completed within the next twelve months. The Amendment did not meet the accounting criteria for debt extinguishment. The Senior Facility bears interest on the outstanding principal balance at an annual rate equal to the Canadian prime rate plus 8.05%, calculated based on the daily outstanding balance of the Senior Facility calculated and compounded monthly in arrears and with no deemed reinvestment of monthly payments. Interest is due monthly throughout the term. The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice. Transaction costs incurred on the Closing Date Draw were $3,306 (C$4,425). There were no fees incurred associated with the Amendment. Transaction costs are deferred and amortized as a component of interest expense over the estimated term using the effective interest rate method. On June 29, 2020, the lender notified the Company that it had exercised its unilateral right to syndicate $19,153 (C$26,000) of the Company’s Senior Facility in the aggregate principal amount of $59,600 (C$79,800). The Senior Facility’s terms otherwise remain unchanged. The Senior Facility has first priority claims on all North American assets of the Company and contains certain affirmative and negative covenants. The operational covenant includes a minimum unrestricted cash threshold of $29,466 (C$40,000) in order for the Company to make additional capital expenditures and investments. The Senior Facility is collateralized against all real and personal property owned, leased and operated by the Company in North America, and any and all other property of the Company now existing and acquired in North America after the closing date. As of September 30, 2020, the Company was in compliance with all covenants set forth under the Senior Facility. The following table sets forth the net carrying amount of the Senior Facility: September 30, 2020 Senior Facility $ 48,299 Unamortized transaction costs (2,355 ) Net carrying amount $ 45,944 Less: current portion of Senior Facility — Total noncurrent portion of Senior Facility $ 45,944 The following table sets forth total interest expense recognized related to the Senior Facility: Three months ended September 30, 2020 Nine months ended September 30, 2020 Contractual interest at Canadian prime plus 8.05% $ 1,260 $ 2,970 Amortization of transaction costs 407 943 Total $ 1,667 $ 3,913

Registered Offering and Warrant

Registered Offering and Warrants	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Registered Offering and Warrants	1 4 . Registered Offering and Warrants On March 17, 2020, the Company closed a registered offering of 7,250,000 shares of the Company’s Class 2 common stock for $4.76 per share with an equal number of accompanying warrants and 11,750,000 pre-funded warrants for $4.7599 (the “pre-funded warrants”) with an equal number of accompanying warrants. The pre-funded warrants had an exercise price per share of Class 2 common stock of $0.0001 and were exercisable at any time after their original issuance and expire on the fifth anniversary date of issuance. As of September 30, 2020, all pre-funded warrants have been exercised. The 19,000,000 total accompanying warrants (the “warrants”) allow the holders to purchase an aggregate of 19,000,000 shares of the Company’s Class 2 common stock. The warrants have an exercise price per share of Class 2 common stock of $5.95 and are exercisable at any time after the first trading day following the six-month The total gross proceeds of the registered offering were $90,439, of which $21,025 was allocated to the Class 2 common stock at the offering close and $69,414 was allocated to the warrant liability. Issuance costs incurred on the registered offering were $5,150, of which $3,953 was recorded to other expenses (income) in the statements of net loss and comprehensive loss and $1,197 was allocated to the Class 2 common stock and recorded net against the allocated gross proceeds in additional paid-in-capital. The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues Class 2 common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. There were no triggering events during the three and nine months ended September 30, 2020. The Company received stockholder approval of the anti-dilution price protection feature at the Company’s Annual Meeting on May 28, 2020. The Company's warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to effect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of Class 2 common stock due to be issued multiplied by any trading price of the Class 2 common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered Class 2 common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise. Pre-funded warrants and warrants outstanding at September 30, 2020, and related activity for the nine months ended September 30, 2020 is as follows (reflects the number of shares of Class 2 common stock as if the warrants were converted to Class 2 common stock): Description Classification Exercise price Expiration date Balance December 31, 2019 Issued Exercised Balance September 30, 2020 Pre-Funded Warrants Liability $ 0.0001 March 17, 2025 — 11,750,000 (11,750,000 ) — Warrants Liability $ 5.95 March 17, 2025 — 19,000,000 — 19,000,000 Total — 30,750,000 (11,750,000 ) 19,000,000 The Company estimated the fair value of the Warrant liability at September 30, 2020 at $3.76 per warrant using the Monte Carlo pricing model (Level 3) with the following weighted-average assumptions: Risk-free interest rate 0.35 % Expected volatility 100 % Expected term 5 years Expected dividend yield 0 % Strike price $ 5.95 Fair value of common stock $ 4.85 Expected volatility is based on the historical volatility of the Company's common stock since its initial public offering in 2018.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	1 5 . Stockholders’ Equity Common and preferred stock The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of September 30, 2020. The liquidation and dividend rights are identical among Class 1 common stock and Class 2 common stock, and all classes of common stock share equally in the Company’s earnings and losses. Par Value Authorized Voting Rights Class 1 common stock $ 0.0001 233,333,333 10 votes for each share Class 2 common stock $ 0.0001 500,000,000 1 vote for each share Preferred stock $ 0.0001 10,000,000 N/A On March 17, 2020, the Company closed the registered offering, issuing 7,250,000 shares of the Company’s Class 2 common stock along with pre-funded warrants and warrants (refer to Note 14). During the period from the close of the registered offering and March 31, 2020, all pre-funded warrants were exercised at a price per share of $0.0001 and the Company issued 11,750,000 shares of Class 2 common stock (refer to Note 14). During the three and nine months ended September 30, 2020, the Company issued 6,781,090 and 9,493,494 shares of Class 2 common stock for gross proceeds of $46,153 and $76,999, respectively, under the at-the-market equity offering. Transaction costs of $1,540 were recorded net against the allocated gross proceeds in additional paid-in-capital. The warrants’ anti-dilution price protection features allow, for the period the warrants are outstanding, the Company to only issue up to $20,000 in aggregate gross proceeds under the Company’s at-the-market offering program at prices less than the exercise price of the warrants, and in no event more than $6,000 per quarter, at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection features. The Company’s future ability to pay cash dividends on Class 2 common stock is limited by the terms of the Senior Facility and cannot be paid without the consent of the lender. On September 30, 2020, 13,159,762 shares of Class 1 common stock, constituting all of the shares of Class 1 common stock that were issued and outstanding, were automatically converted into shares of Class 2 common stock, as the Class 1 common stock ceased to represent at least 10% of the outstanding common stock. Prior to the conversion, the Company had authorized 250,000,000 shares of Class 1 common stock. Upon conversion, 16,666,667 were retired, leaving 233,333,333 shares authorized, par value $0.0001 per share. There are no shares of Class 1 common stock outstanding as of September 30, 2020.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	1 6 . Stock-based Compensation Original Stock Option Plan Certain employees of the Company participated in the equity-based compensation plan of Privateer Holdings, Inc. (the “Original Plan”) under the terms and valuation method detailed in the Company’s annual financial statements. For the three and nine months ended September 30, 2020, the total stock-based compensation expense associated with the Original Plan was $114 and $410 (2019 – $143 and $411). As of September 30, 2020, the total remaining unrecognized stock-based compensation expense related to non-vested stock options under the Original Plan amounted to $375 which will be recognized over the weighted-average remaining requisite service period of approximately 0.8 years. Stock option activity under the Original Plan is as follows: Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 3,014,004 $ 3.04 5.8 $ 44,108 Exercised (528,261 ) 1.15 Forfeited (62,153 ) 4.44 Cancelled (125,999 ) 3.30 Balance September 30, 2020 2,297,591 $ 3.38 3.8 $ 32,717 Vested and expected to vest, September 30, 2020 2,299,283 $ 3.37 3.8 $ 32,742 Vested and exercisable, September 30, 2020 2,198,632 $ 3.22 3.7 $ 31,750 No stock options were granted under the Original Plan during the nine months ended September 30, 2020 and September 30, 2019. The total fair value of stock options vested as of September 30, 2020 was $118 (December 31, 2019 – $2,789). New Stock Option and Restricted Stock Unit Plan The number of shares of Class 2 common stock reserved for issuance under the 2018 Equity Incentive Plan (the “2018 EIP”) automatically increases on January 1 of each calendar year, for a period of not more than ten years, starting on January 1, 2019 and ending on and including January 1, 2027, in an amount equal to 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the prior calendar year, or a lesser number of shares determined by the Company’s Board of Directors. The shares reserved include only the outstanding shares related to stock options and RSUs and excludes stock options outstanding under the Original Plan. The number of shares reserved for issuance under the 2018 EIP is 17,037,421 , effective as of January 1, 2020 (December 31, 2019 – 12,926,172 ). For the three and nine months ended September 30, 2020 , total stock-based compensation expense associated with the 2018 EIP was $ 7,966 and $ 22,994 (2019 - $ 8,501 and $ 21,892 ). As of September 30 , 2020, the total remaining unrecognized s tock-based compensation expense related to non-vested stock options and restricted stock units (“RSUs”) under the 2018 EIP amounted to $ 40,805 which will be recognized over the weighted average remaining requisite service period of approximately 1.03 years . Stock option and RSU activity under the 2018 EIP are as follows: Time-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 5,307,130 $ 14.04 8.4 $ 44,297 Granted — — Exercised (286,948 ) 7.76 Forfeited (245,222 ) 13.93 Cancelled (193,127 ) 13.11 Balance September 30, 2020 4,581,833 $ 14.48 7.6 $ — Vested and expected to vest, September 30, 2020 4,511,481 $ 14.32 7.5 $ — Vested and exercisable, September 30, 2020 3,276,183 $ 12.47 7.6 $ — During the nine months ended September 30, 2020 , no time-based stock options were granted under the 2018 EIP (2019 – 10,000). The weighted-average fair values of stock options granted during the nine months ended September 30, 2020 was $0 per share (2019 – $12.01). Performance-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 520,000 $ 7.76 8.4 $ 4,872 Granted — — — Exercised (320,000 ) 7.76 Forfeited — — — Cancelled — — — Balance September 30, 2020 200,000 $ 7.76 7.6 $ — Vested and expected to vest, September 30, 2020 200,000 $ 7.76 7.6 $ — Vested and exercisable, September 30, 2020 200,000 $ 7.76 7.6 $ — No performance-based stock options were granted under the 2018 EIP during the nine months ended September 30, 2020 and September 30, 2019. The total fair value of stock options vested as of September 30, 2020 was $0 (December 31, 2019– $1,246). Time-based RSU activity Time-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 1,423,392 $ 42.05 Granted 2,024,334 8.67 Vested (396,051 ) 45.32 Forfeited (785,641 ) 27.88 Cancelled (17,711 ) 31.31 Non-vested September 30, 2020 2,248,323 $ 16.46 During the nine months ended September 30, 2020, 2,024,334 (2019 – 944,616) time-based RSUs were granted. During the nine months ended September 30, 2020, 396,051 (2019 – 54,635) time-based RSUs vested. Performance-based RSUs activity Performance-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 265,625 $ 7.76 Granted 448,230 7.05 Vested (159,375 ) 7.76 Non-vested September 30, 2020 554,480 $ 7.19 448,230 performance-based RSUs were granted during the nine months ended September 30, 2020 (2019 – none). During the nine months ended September 30, 2020, 159,375 (2019 – 731,250) performance-based RSUs vested.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) (AOCI)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) (AOCI)	1 7 . Accumulated Other Comprehensive Income (Loss) (“AOCI”) The components of AOCI, net of tax, were as follows: Foreign Currency Translation Adjustments Unrealized (loss) gain on available-for-sale debt securities Total Balance as at December 31, 2019 $ 10,021 $ (302 ) $ 9,719 Other comprehensive loss: Change in foreign currency translation (16,633 ) — (16,633 ) Change in unrealized (losses)/ gains on available-for-sale debt securities — (74 ) (74 ) Balance as at March 31, 2020 $ (6,612 ) $ (376 ) $ (6,988 ) Other comprehensive loss: Change in foreign currency translation 7,184 — 7,184 Change in unrealized gains on available-for-sale debt securities — 35 35 Balance as at June 30, 2020 $ 572 $ (341 ) $ 231 Other comprehensive loss: Change in foreign currency translation 2,265 — 2,265 Change in unrealized gains on available-for-sale debt securities — 193 193 Balance as at September 30, 2020 $ 2,837 $ (148 ) $ 2,689

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	1 8 . Commitments and Contingencies Legal proceedings In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. The Company records a loss contingency if the information available indicates that it is probable that a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. As of September 30, 2020, in the opinion of management, no claims meet the criteria to record a loss contingency. Lease commitments The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2027. Maturities of lease liabilities: Year ending December 31, Operating Leases Finance Leases 2020 (remaining three months) $ 941 $ 235 2021 3,576 950 2022 3,019 5,389 2023 2,911 11,128 2024 2,489 — Thereafter 8,049 — Total lease payments $ 20,985 $ 17,702 Imputed interest 2,175 3,207 Obligations recognized $ 18,810 $ 14,495 Purchase commitments The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of September 30, 2020: Total 2020 (remaining three months) 2021 2022 2023 2024 Thereafter Purchase commitments $ 99,993 $ 69,732 $ 30,185 $ 38 $ 38 $ — $ — Total $ 99,993 $ 69,732 $ 30,185 $ 38 $ 38 $ — $ — In 2018, the Company signed an agreement with Rose Lifescience Inc. (“Rose”) for distribution and marketing of product in Quebec in exchange for a minimum fee of $384 per annum for an initial term of five years, and agreed to purchase the lesser of 2,000 Kg per year or 40% of the production of Cannabis at a rate of 115% of cost of goods sold from the Rose facility. In September 2020, the Company signed an amendment to this agreement and the estimated compensation fee is approximately $10,350 through 2023. As there is no firm commision fee commitment, it is excluded from the above schedule. Compensation fee expense is recorded as incurred. In 2018, the Company entered into a Product and Trademark License Agreement with Docklight LLC, a related party (refer to Note 22), to use certain intellectual property rights in exchange for payment of royalty depending upon specified percentage of licensed product net sales. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule. Other commitments The Company has payments on the ABG finance liability (refer to Note 11), convertible notes (refer to Note 12) and the Senior Facility (refer to Note 13) as follows: Total 2020 (remaining three months) 2021 2022 2023 2024 Thereafter ABG finance liability $ 7,500 $ — $ 1,500 $ 1,500 $ 1,500 $ 1,500 $ 1,500 Convertible notes, principal and interest 546,251 5,938 23,750 23,750 492,813 — — Senior Facility, principal and interest 55,483 1,268 5,071 49,144 — — — Portugal construction commitments 4,927 4,927 Total $ 614,161 $ 12,133 $ 30,321 $ 74,394 $ 494,313 $ 1,500 $ 1,500

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customers	1 9 . Revenue from Contracts with Customers The Company reports two segments: cannabis and hemp, in accordance with ASC 280 Segment Reporting. The Company generates revenues from the cannabis and hemp segments through contracts with customers, each with a single performance obligation, being the sale of products. The Company determines that revenue information disclosed in business segment information in Note 25 disaggregates revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. For certain long-term arrangements, the Company has performance obligations for goods it has not yet delivered. For these arrangements, the Company does not have a right to bill for the undelivered goods. The Company has determined that any unbilled consideration relates entirely to the value of undelivered goods. Accordingly, the Company has not recognized revenue, and has elected not to disclose amounts, related to these undelivered goods. As of September 30, 2020 and December 31, 2019, other than accounts receivable, net of allowance for credit losses and provision for sales returns, the Company has no contract balances in the balance sheets.

General and Administrative Expe

General and Administrative Expenses	9 Months Ended
	Sep. 30, 2020
General And Administrative Expense [Abstract]
General and Administrative Expenses	20 . General and Administrative Expenses General and administrative expenses are comprised of the following items: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Salaries $ 8,323 $ 8,637 $ 24,365 $ 22,289 Other expenses 2,367 4,261 12,803 10,651 Professional fees 1,407 6,051 9,750 12,716 Loss on disposal of property and equipment 457 — 885 112 Travel expenses 132 1,448 939 3,330 Credit loss (recovery) expenses (21 ) (275 ) 288 520 Total $ 12,665 $ 20,122 $ 49,030 $ 49,618

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	2 1 . Supplemental Cash Flow Information Nine months ended September 30, 2020 2019 Cash paid for interest $ 10,367 $ 17,613 Cash paid for income taxes $ 272 $ — Non-cash investing Acquisition of Manitoba Harvest $ — $ 157,917 Acquisition of Natura $ — $ 38,980 Investment in ABG Profit Participation Arrangement, net of receivable $ — $ 94,805 Purchases of investments and S&S acquisition $ — $ 14,508 Nine months ended September 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,672 $ 1,524 Operating cash flows from finance leases $ 445 $ — Financing cash flows from finance leases $ 309 $ — Non-cash additions to Right-of-use assets and lease liabilities Operating leases $ 423 $ 14,897 Finance leases $ — $ —

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	2 2 . Related Party Transactions In the normal course of business, the Company enters into related party transactions with certain entities under common control and joint ventures as described in the Annual Financial Statements and detailed below. Leafly Holdings, Inc. (“Leafly”) The Company has an agreement with Leafly providing for data licensing activities. During the three and nine months ended September 30, 2020, operational expenses of $5 and $134 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $130 and $149). Docklight LLC (“Docklight”) The Company pays Docklight a royalty fee pursuant to a brand licensing agreement which provides the Company with exclusive rights in Canada for the use of certain adult-use brands. During the three and nine months ended September 30, 2020, royalty fees of $331 and $748 were recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $44 and $176). Refer to Note 18 for purchase commitments with Docklight. Ten Eleven Management LLC (“Ten Eleven”) In January 2020, the Company entered into a corporate services agreement with Ten Eleven Management LLC (“Ten Eleven”), pursuant to which Ten Eleven provides the Company with certain general administrative and corporate services for a service fee. This agreement was terminated in April 2020. In August 2020, the Company entered into a corporate services agreement with Ten Eleven pursuant to which Ten Eleven provides the Company with certain accounting services for a service fee. This agreement was terminated in October 2020. During the three and nine months ended September 30, 2020, management services of $- and $71 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $75 and $200). The Company sub-leases a portion of certain office space to Ten Eleven. Ten Eleven’s lease payments are based on the pro-rata share of space that they occupy, with annual lease payments of $470. The sub-lease was terminated in May 2020 Fluent and Cannfections The Company has joint venture arrangements with a 50% ownership and voting interest in each of Fluent and Cannfections. Refer to Note 6 for details over transactions with these entities for the nine months ended September 30, 2020. Aircraft Time Share Reimbursement The Company had entered into an aircraft time-share agreement and a lease consent and subordination agreement with Brendan Kennedy, our Chief Executive Officer, whereby the Company had access to and use of an aircraft owned by Mr. Kennedy on an as-needed basis for business purposes. Pursuant to this arrangement, the Company reimbursed Mr. Kennedy for certain related aircraft expenses. During the three and nine months ended September 30, 2020, the Company incurred $0 and $261 of fees which is included in general and administrative expenses (2019 – $0 and $0). Accounts payable due to related parties At September 30, 2020, the Company has accounts payable due to related parties of $141 (December 31, 2019 - $68).

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2020
Investments All Other Investments [Abstract]
Financial Instruments	2 3 . Financial Instruments Credit risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents are deposited in major financial institutions in Canada, Australia, Portugal, Germany and the United States. To date, the Company has not experienced any losses on its cash deposits. Accounts receivable are unsecured and the Company does not require collateral from its customers. The Company is also exposed to credit risk from the potential default by any of its counterparties on its financial assets. The Company evaluates the collectability of its accounts receivable and provides an allowance for credit losses as necessary (refer to Note 7). Due to the uncertainties associated with COVID-19, the Company may be unable to accurately predict the creditworthiness of its counterparties and their ability to meet their obligations. This may result in unforeseen additional credit losses. Foreign currency risk The Company conducts its business in several countries and in a variety of currencies, the most significant of which are the Canadian dollar and Euro. Consequently, the Company is exposed to foreign currency risk. A significant portion of the Company’s assets, liabilities, revenue, and expenses are denominated in Canadian dollars. A 10% change in the exchange rates for the Canadian dollar would affect the carrying value of net assets by approximately $23,578 as of September 30, 2020, with a corresponding impact to accumulated other comprehensive income (loss). The Company is also exposed to risk related to changes in the value of the Euro due to its construction commitment in Portugal. Interest rate risk The Company’s exposure to changes in interest rates relates primarily to the Company’s outsanding debt. The Company is exposed to changes to the Canadian prime rate as the Senior Facility bears interest based on the Canadian prime rate plus 8.05%. The convertible notes bear interest at a fixed rate of 5% and are not publicly traded and, therefore, are not affected by changes in the market interest rates. A 1% change in the Canadian prime rate would have an impact of $127 and $295 to the statements of net loss and comprehensive loss for the three and nine months ended September 30, 2020. Liquidity risk The Company’s objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash flows generated from operations to meet its requirements. As of September 30, 2020, the most significant financial liabilities are accounts payable, accrued expenses and other current liabilities, convertible notes and the Senior Facility.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	2 4 . Fair Value Measurement The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total As of September 30, 2020 Investments Equity investments measured at fair value $ 2,207 $ — $ — $ 2,207 Debt securities classified as available-for-sale 844 — 4,921 5,765 Warrant liability — — (71,636 ) (71,636 ) Total recurring fair value measurements $ 3,051 $ — $ (66,715 ) $ (63,664 ) Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total As of December 31, 2019 Investments Equity investments measured at fair value $ 4,183 $ — $ — $ 4,183 Debt securities classified as available-for-sale 727 — 4,320 5,047 Acquisition-related contingent consideration — — (420 ) (420 ) Total recurring fair value measurements $ 4,910 $ — $ 3,900 $ 8,810 Items measured at fair value on a recurring basis The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability. Debt securities classified as available-for-sale and equity investments recorded at fair value: The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows. Warrant liability: The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Monte Carlo pricing model (refer to Note 14). Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of Class 2 common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability,. The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows: Debt securities classified as available-for- sale Warrant liability Opening balance as at December 31, 2019 $ 4,320 $ — Additions and settlements Additions — (69,414 ) Exercise — 49,053 Total gains or losses for the period: — — Included in net loss — — Interest expenses, net 601 — Change in fair value of warrant liability — (51,275 ) Impairment of assets — — Foreign currency translation loss, net — — Closing balance as at September 30, 2020 $ 4,921 $ (71,636 ) Quantitative information about Level 3 fair value measurements Fair value at September 30, 2020 Valuation technique Unobservable input Range (weighted average) Discount rate 16.5% Debt securities classified as available-for-sale $ 4,921 Discounted cash flow Probability of conversion/ prepayment nil Probability of default nil Warrant liability $ (71,636 ) Monte Carlo Volatility 100% Expected life 0.2 years to 5 years (2.4 years) Items measured at fair value on a non-recurring basis The Company's prepayments and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. Land and buildings (held for sale): The Company used a third-party real estate agent to assist management in its determination of the fair value of the assets held for sale at the High Park Gardens facility. Management, in its determination of the fair value of the assets held for sale reviewed market data from recent sales of similar properties to determine an implied sale price per acre of land and greenhouse space and wrote-down the carrying value of the land and greenhouse space held for sale to the estimated fair value less selling costs. In connection with an evaluation of such assets during the nine months ended September 30, 2020, the carrying values of the land and buildings at the High Park Gardens facility (Level 2), ABG finance receivable and certain intangible assets (Level 3) were concluded to exceed their fair values. As a result, the Company recorded impairment charges that incorporates fair value measurements based on Level 2 (refer to Note 2) and Level 3 inputs (refer to Note 3, Note 8 and Note 10). The estimated fair value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other current liabilities, convertible notes and Senior Facility at September 30, 2020 (December 31, 2019 – the fair value of all aforementioned, except the Senior Facility which was entered into in 2020) approximate their carrying value.

Business Segment Information

Business Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Business Segment Information	2 5 . Business Segment Information The Company has two operating segments based on major product categories: cannabis and hemp. These operating segments are also the Company’s reportable segments. The cannabis segment cultivates, processes and distributes medical and adult-use cannabis products in a variety of formats, as well as related accessories, on a global basis. The hemp segment processes and distributes a diverse portfolio of hemp-based natural and organic food and wellness products on a global basis. The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and gross profit as the measure of segment profit or loss. The accounting policies of each segment are the same as those set out under the summary of significant accounting policies in Note 1. There are no intersegment sales or transfers. The comparative three and nine months ended September 30, 2019 have been recast to reflect to the current segment structure. Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Revenue Gross profit / (loss) Revenue Gross profit Revenue Gross profit / (loss) Revenue Gross profit Cannabis $ 31,426 $ (4,717 ) $ 35,451 $ 9,225 $ 92,373 $ (13,863 ) $ 78,876 $ 16,213 Hemp $ 19,980 $ 8,456 $ 15,650 $ 6,628 $ 61,549 $ 23,053 $ 41,167 $ 17,298 Total $ 51,406 $ 3,739 $ 51,101 $ 15,853 $ 153,922 $ 9,190 $ 120,043 $ 33,511 No asset information is provided for the segments because the Company’s chief operating decision maker does not review this information by segment on a regular basis. Total revenue and gross profit for the reportable segments is equal to the Company’s consolidated revenue and gross profit. Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Gross profit for the segments $ 3,739 $ 15,853 $ 9,190 $ 33,511 General and administrative expenses 12,665 20,122 49,030 49,618 Sales and marketing expenses 10,000 16,974 40,709 39,161 Research and development expenses 921 2,315 2,831 4,891 Depreciation and amortization expenses 3,425 3,200 10,353 7,457 Stock-based compensation expenses 8,080 8,644 23,404 22,303 Impairment of assets — — 58,210 — Acquisition-related expenses (income), net — (13,454 ) — (6,566 ) Loss from equity method investments 1,420 1,837 4,495 1,837 Foreign exchange (gain) loss, net (9,319 ) 2,585 5,424 1,153 Change in fair value of warrant liability (31,913 ) — 51,275 — Interest expenses, net 10,437 8,680 30,147 26,005 Finance income from ABG — (210 ) — (557 ) Other expense (income), net (38 ) (1,116 ) 4,944 (6,185 ) Loss before income taxes $ (1,939 ) $ (33,724 ) $ (271,632 ) $ (105,606 ) Sources of revenue were as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Dried cannabis $ 21,079 $ 29,412 $ 61,339 $ 62,214 Cannabis extracts 10,239 5,819 30,246 16,172 Hemp products 19,980 15,650 61,549 41,167 Accessories and other 108 220 788 490 Total $ 51,406 $ 51,101 $ 153,922 $ 120,043 Channels of revenue were as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Cannabis Adult-use $ 19,926 $ 15,835 $ 58,466 $ 38,758 Canada - medical 3,399 3,898 11,285 9,222 International - medical 8,101 5,708 22,220 9,370 Bulk — 10,010 402 21,526 Total Cannabis revenue $ 31,426 $ 35,451 $ 92,373 $ 78,876 Hemp 19,980 15,650 61,549 41,167 Total $ 51,406 $ 51,101 $ 153,922 $ 120,043 Revenue attributed to geographic region based on the location of the customer was as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Canada $ 29,475 $ 33,585 $ 86,807 $ 81,138 United States 13,340 10,836 43,851 28,407 Other countries 8,591 6,680 23,264 10,498 Total $ 51,406 $ 51,101 $ 153,922 $ 120,043 Revenue includes excise duties of $4,213 and $13,325 for the three and nine months ended September 30, 2020 (2019: $2,931 and $8,707). Long-lived assets consisting of property and equipment, net of accumulated depreciation, attributed to geographic regions based on their physical location were as follows: September 30, 2020 December 31, 2019 Canada $ 115,711 $ 144,065 Portugal 67,198 36,908 United States 4,659 3,171 Other countries 62 73 Total $ 187,630 $ 184,217 Two customers accounted for 21% and 19% of revenue, respectively, for the three months ended September 30, 2020. Three customers accounted for 20%, 18% and 11% of revenue, respectively, for the nine months ended September 30, 2020. Three customers accounted for 20%, 14%, and 10% of revenue, respectively, for the three months ended September 30, 2019. Two customers accounted for 12% and 11%, of revenue, respectively, for the nine months ended September 30, 2019. Two customers accounted for 20% and 11%, respectively, of the Company’s accounts receivable balance, as of September 30, 2020. Two customers accounted for 20% and 10%, respectively, of the Company’s accounts receivable balance as of December 31, 2019.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	2 6 . Subsequent Events As of September 30, 2020, Tilray holds 8,532,243 shares of stock in Kiaro Brands Inc. (Kiaro) at a balance of $3,600 within Other Investments. Effective October 13, 2020, Kiaro went public as Kiaro Holdings Corp. (Ticker: KO) on the TSX Venture Exchange at a price of CAD $0.17 per share. The completion of this transaction will impact the manner the Company assesses the fair value reporting of its investment, which will continue to be presented within Other Investments.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Description of the Business	Description of the business Tilray, Inc. and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, “our”, or “us”) is a global medical cannabis research, cultivation, processing and distribution organization, and is one of the leading suppliers of adult-use cannabis in Canada. The Company also markets and distributes food products from hemp seed and offers a broad range of natural and organic hemp based food products and ingredients that are sold through retailers and websites globally.
Basis of Presentation and Going Concern	Basis of presentation and going concern The accompanying unaudited condensed consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. These financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due. For the three and nine months ended September 30, 2020, the Company reported a consolidated net loss of $2,316 and $268,124, and a net loss of $36,351 and $102,021 for the three and nine months ending September 30, 2019. For the nine months ended September 30, 2020, the Company had cash flows used in operating activities of $104,486 and cash flows used in operating activities of $167,255 for the nine months ended September 30, 2019. As at September 30, 2020 and December 31, 2019 the Company had working capital of $171,349 and $166,600, respectively. Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the current cash on hand for the next twelve months from the date of issuance of these financial statements. On March 17, 2020, the Company received net proceeds of $85,289 ($90,439 of gross proceeds) from its registered equity offering (refer to Note 14). 19,000,000 warrants were issued as part of the offering. All the warrants remain outstanding as of September 30, 2020. The warrants issued contain an anti-dilution provision that was approved by a vote of the Company’s stockholders at its Annual Meeting held on May 28, 2020. While the Company has the ability to issue securities under its at-the-market program, because warrants from the equity offering remain outstanding as of September 30, 2020, the Company may only issue up to $20,000 in aggregate gross proceeds under its at-the-market offering program at prices less than the exercise price of the warrants (currently $5.95 per share), and in no event more than $6,000 per quarter at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection feature. During the three months ended September 30, 2020, the Company received gross proceeds of $46,153 from shares sold under its at-the-market offering program. All shares were sold at share prices above $5.95 per share. On February 28, 2020, the Company completed a debt financing under its Senior Facility with maximum aggregate principal amount of $59,600 and borrowed an aggregate principal amount of $49,700. The Senior Facility provided for an additional draw of $9,900. On June 5, 2020, as a result of COVID-19 related financial markets conditions that affected the lender and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that Tilray withdraw its then outstanding request for the additional draw of $9,900 and entered into an amendment to its Senior Facility which provides for, among other things, interest-only payments for the remainder of its term with all outstanding principal payments due at February 28, 2022 (refer to Note 13). As of September 30, 2020, the Company had cash and cash equivalents of $155,205. During the last nine months management has implemented a series of cost reduction strategies including headcount reductions and the closure of certain facilities. Currently, management’s forecasts and related assumptions indicate that the Company will remain in compliance with all its debt covenants and, over the next twelve months from the date of issuance of these financial statements, will be able to satisfy all its contractual obligations such as payment of interest on the 5% convertible notes (refer to Note 12 and Note 18), interest-only payments on the Senior Facility (refer to Note 13 and Note 18), non-cancelable minimum purchase commitments for inventory (refer to Note 18), payment of the ABG finance liability (refer to Note 18), payment of the Company’s lease commitments (refer to Note 18) and payment of the Company’s Portugal construction commitments (refer to Note 18). Due to uncertainties the Company may face in raising additional equity financing in the future, which may be further impacted by the economic downturn and unprecedented conditions due to COVID-19, there remains uncertainty about the impact this may have on management ’ s assumptions used to develop these forecasts. Accordingly, the Company has concluded it is probable that it can implement plans that would effectively mitigate the conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern for the next twelve months. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to successfully implement its initiatives. Any such adjustments could be material. Changes in comparative presentation The Company lost its emerging growth company status effective December 31, 2019 and therefore reported as a large accelerated filer in the Annual Financial Statements. As a result, the Company complies with new and revised accounting standards applicable to public companies. In the fourth quarter of 2019, the Company adopted the following accounting pronouncements issued by FASB: ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”); ASU 2016-02, Leases, codified as ASC 842 (“ASC 842”); ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU, codified as ASC 606 (“ASC 606”); and ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), as described in the Annual Financial Statements, with an effective date of January 1, 2019. The comparative three and nine months ended September 30, 2019 included in the financial statements reflect the new and revised accounting standards and therefore does not mirror the September 30, 2019 interim period condensed consolidated financial statements previously filed. The impact to the statements of net loss and comprehensive loss for the three and nine months ended September 30, 2019 is as follows: Three months ended September 30, 2019 Nine months ended September 30, 2019 Net loss Other comprehensive (loss) income Net (loss) income Other comprehensive (loss) income Unadjusted $ (35,678 ) $ (5,164 ) $ (101,032 ) $ (2,069 ) Impact of adoption of accounting standards: ASU 2016-01 (312 ) 312 265 (265 ) ASC 842 (32 ) — (157 ) — ASU 2018-07 (329 ) — (1,097 ) — ASC 606 — — — — Adjusted $ (36,351 ) $ (4,852 ) $ (102,021 ) $ (2,334 ) The statement of net loss and comprehensive loss for the three and nine months ended September 30, 2019 was reclassified to conform to the current period’s presentation. In addition, unrelated to the impact of adoption of accounting standards, cost of sales, which was formerly presented as a single line item, is separated between product costs and inventory valuation adjustments. Loss on disposal of property and equipment, formerly presented in other expenses (income) is now presented in general and administrative expenses.
Assets Held for Sale	Assets held for sale In May 2020, the Company announced its decision to close the High Park Gardens facility in response to its anticipated future product needs and the current economic climate. As a result, the Company adopted an accounting policy for assets held for sale. Assets held for sale are accounted for in accordance with applicable accounting guidance provided in ASC Topic 360, Property, Plant and Equipment. The Company classifies its assets as held for sale if, among other criteria, the carrying amount will be recovered principally through a sale transaction rather than continued use and a sale is considered probable and within one year. Assets classified as held for sale are measured at the lower of the carrying amount and fair value less costs to sell. An impairment loss is recognized in impairment of assets through the statements of net loss and comprehensive loss for any initial or subsequent write-down of the asset to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset, but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the asset is recognized at the date of derecognition. Assets are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities classified as held for sale continue to be recognized. Assets classified as held for sale are combined and presented separately from the other assets in the balance sheets.
Allowance for Credit Losses	Allowance for credit losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This guidance was subsequently amended by ASU 2018-19, Codification Improvements, ASU 2019- 04, Codification Improvements, ASU 2019-05, Targeted Transition Relief, ASU 2019-10, Effective Dates, and ASU 2019-11, Codification Improvements. These ASUs are referred to collectively as the new guidance on current expected credit loss (“CECL”). As a result of the adoption of the new CECL guidance on January 1, 2020, the Company has changed its accounting policy for the allowance for credit losses, as it relates to accounts receivable and available-for-sale debt securities. The adoption of the CECL guidance did not have a material impact on the consolidated financial statements at January 1, 2020. Accounts receivable – The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses. The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classes and the expected future loss. This assessment incorporates all available information relevant to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts. As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class. Available-for-sale debt securities
Disclosure Framework - Fair Value Measurement	Disclosure framework - fair value measurement In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) (“ASU 2018-13”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC Topic 820, (b) the policy for timing of transfers between levels, and (c) the valuation process used for Level 3 fair value measurements. ASU 2018-13 also adds, among other items, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The Company adopted ASU 2018-13 effective January 1, 2020 and such adoption did not have a material effect on its financial statements.
Warrants	Warrants In March 2020, the Company closed on a registered offering including Class 2 common stock, warrants, and pre-funded warrants (refer to Note 14). Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company's warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each balance sheet date until settlement and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of net loss and comprehensive loss. Transaction costs allocated to warrants that are presented as a liability are expensed immediately within other expenses (income) in the statements of net loss and comprehensive loss.
Use of Estimates and Significant Judgements	Use of estimates and significant judgements Assets held for sale – The Company uses a third party real estate agent to assist management in its determination of the fair value of the assets held for sale. The Company estimates the fair value by reviewing market data from recent sales of similar properties and determining an implied sale price per acre of land and greenhouse space. Allowance for credit losses – The Company’s projections of expected credit losses are inherently uncertain, and as a result the Company cannot predict with certainty the amount of such losses. Changes in economic conditions, the risk characteristics and composition of the portfolio, bankruptcy laws, and other factors could impact the actual and projected expected credit losses and the related allowance for credit losses. Actual losses may vary from current estimates. Due to potential COVID-19 disruptions in the marketplace it is possible the Company may experience unforeseen and greater credit losses than anticipated or experienced historically. Warrant liability – The Company estimates the fair value of the warrant liability using a Monte Carlo pricing model. The Company is required to make assumptions and estimates in determining an appropriate risk-free interest rate, volatility, term, dividend yield and discount due to exercise restrictions and fair value of common stock.
Net Loss Per Share	Net loss per share Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential additional dilutive common share equivalents consist of warrants, stock options, restricted stock units (“RSUs”) and restricted stock awards. In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. As of September 30, 2020, there were 13,141,298 common share equivalents with potential dilutive impact (September 30, 2019 – 8,043,920). Because the Company is in a net loss for all periods presented in these financial statements, there is no difference between the Company’s basic and diluted net loss per share for the periods presented.
New Accounting Pronouncements Not Yet Adopted	New accounting pronouncements not yet adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU. In January 2020, the FASB issued ASU 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying generally accepted accounting principles (GAAP) for certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 is effective for the Company beginning January 1, 2022. The Company is currently evaluating the effect of adopting this ASU.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Impact to Statements of Net Loss and Comprehensive Loss	The impact to the statements of net loss and comprehensive loss for the three and nine months ended September 30, 2019 is as follows: Three months ended September 30, 2019 Nine months ended September 30, 2019 Net loss Other comprehensive (loss) income Net (loss) income Other comprehensive (loss) income Unadjusted $ (35,678 ) $ (5,164 ) $ (101,032 ) $ (2,069 ) Impact of adoption of accounting standards: ASU 2016-01 (312 ) 312 265 (265 ) ASC 842 (32 ) — (157 ) — ASU 2018-07 (329 ) — (1,097 ) — ASC 606 — — — — Adjusted $ (36,351 ) $ (4,852 ) $ (102,021 ) $ (2,334 )

Assets Held for Sale (Tables)

Assets Held for Sale (Tables)	9 Months Ended
	Sep. 30, 2020
Assets Of Disposal Group Including Discontinued Operation [Abstract]
Summary of Assets Comprising Disposal Group Classified as Held for Sale	The carrying amount of major classes of assets comprising the disposal group classified as held for sale are as follows: As of September 30, 2020 Assets classified as held for sale Land and buildings $ 6,797 Cultivation license — Total assets held for sale $ 6,797
Summary of Pretax (Loss) Income Continuing Operations	The following table provides summary pretax (loss) income for the High Park Gardens facility, which are included in continuing operations for their respective periods: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Pre-tax (loss) income $ (642 ) $ 119 $ (28,335 ) $ (396 )

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory is comprised of the following items: September 30, 2020 December 31, 2019 Raw materials $ 15,338 $ 15,926 Work-in-process 59,863 53,973 Finished goods 14,716 17,962 Total $ 89,917 $ 87,861
Schedule of Inventory Valuation Adjustments Included in Cost of Sales	Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Raw materials $ 173 $ — $ 384 $ — Work-in-process 11,164 201 30,656 726 Finished goods 2,106 — 5,076 — Total $ 13,443 $ 201 $ 36,116 $ 726

Prepayments and Other Current_2

Prepayments and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Prepaid Expense And Other Assets Current [Abstract]
Schedule of Prepayments and Other Current Assets	Prepayments and other current assets are comprised of the following items: September 30, 2020 December 31, 2019 Deposits $ 15,325 $ 25,490 Prepayments 6,854 5,847 Taxes receivable 5,975 6,165 ABG finance receivable - current — 671 Total $ 28,154 $ 38,173

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Long-term Investments	Long-term investments are comprised of the following items: September 30, 2020 December 31, 2019 Equity investments at fair value $ 2,207 $ 4,183 Equity investments under measurement alternative 14,738 14,954 Debt securities classified under available-for-sale method 5,765 5,047 Total other investments $ 22,710 $ 24,184
Summary of Ownership Interests in Equity Method Investments	The Company’s ownership interests in its equity method investments as of September 30, 2020 and December 31, 2019 and (loss) gain from equity method investments for the nine months ended September 30, 2020 were as follows: Approximate Carrying value (Loss) gain from equity method investments for the nine months ended ownership % September 30, 2020 September 30, 2020 Investment in Fluent 50% $ 5,147 $ (4,725 ) Investment in Cannfections 50% 3,764 230 Total equity method investments $ 8,911 $ (4,495 ) Approximate Carrying value (Loss) gain from equity method investments for the nine months ended ownership % December 31, 2019 September 30, 2019 Investment in Fluent 50% $ 7,836 $ (1,837 ) Investment in Cannfections 50% 3,612 — Total equity method investments $ 11,448 $ (1,837 )
Summary of Financial Information for Equity Method Investments	Summary financial information for the Company’s equity method investments on an aggregate basis is as follows: September 30, 2020 December 31, 2019 Current assets $ 12,346 $ 13,942 Noncurrent assets $ 5,205 $ 4,987 Current liabilities $ 4,965 $ 1,561 Noncurrent liabilities $ — $ — Nine months ended September 30, 2020 2019 Revenue $ 4,854 $ — Gross profit $ 2,032 $ — Net loss $ (8,991 ) $ (3,160 )

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2020
Allowance For Credit Loss [Abstract]
Schedule of Allowance for Credit Losses	The following table provides activity in the allowance for credit losses for the nine months ended September 30, 2020: Allowance for credit losses, January 1, 2020 $ 615 Provision for expected credit losses (1) 288 Write-offs charged against allowance (74 ) Recoveries of amounts previously written off — Foreign currency translation adjustment (3 ) Allowance for credit losses, September 30, 2020 $ 826 Accounts receivable balance before allowance for credit losses and provision for sales returns, September 30, 2020 $ 26,843 (1) The provision for expected credit losses is recorded in general and administrative expenses.
Schedule of Fair Value and Unrealized Loss of Investment	The following table provides the fair value and unrealized loss of the investment at September 30 , 2020 and December 31, 2019: September 30, 2020 December 31, 2019 Fair value $ 1,124 $ 945 Unrealized loss $ 148 $ 302

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net consists of the following: September 30, 2020 December 31, 2019 Land $ 6,488 $ 6,417 Buildings and leasehold improvements 108,021 109,172 Laboratory and manufacturing equipment 34,500 31,173 Office and computer equipment 1,779 2,659 Right-of-use assets under finance lease 14,415 14,753 Construction-in-process, not yet available for use 46,551 37,160 211,754 201,334 Less: accumulated depreciation (24,124 ) (17,117 ) Total $ 187,630 $ 184,217

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill Disclosure [Abstract]
Schedule of Change in Carrying Amount of Goodwill	The following table shows the change in carrying amount of goodwill: Hemp Cannabis Total Balance as of December 31, 2019 $ 133,314 $ 29,937 $ 163,251 Foreign currency translation adjustment (2,971 ) (685 ) (3,656 ) Balance as of September 30, 2020 $ 130,343 $ 29,252 $ 159,595

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Intangible Assets Net Excluding Goodwill [Abstract]
Schedule of Intangible Assets	Intangible assets are comprised of the following items: September 30, December 31, 2020 2019 Cost Accumulated Amortization Impairment Net Cost Accumulated Amortization Impairment Net Definite-lived intangible assets: Patent $ 669 $ 131 $ 538 $ — $ 716 $ 99 $ — $ 617 Customer relationships 132,837 13,241 — 119,596 135,953 7,132 — 128,821 Developed technology 6,912 1,094 — 5,818 7,074 590 — 6,484 Websites 5,126 3,921 — 1,205 5,157 3,331 — 1,826 Trademarks and licenses 9,052 1,293 7,650 109 9,135 925 — 8,210 Total 154,596 19,680 8,188 126,728 158,035 12,077 — 145,958 Indefinite-lived intangible assets: Cultivation license 10,239 — 10,239 — 10,689 — — 10,689 Alef license — — — — 4,086 — 4,086 — Trademarks 54,125 — — 54,125 55,416 — — 55,416 Rights under ABG Profit Participation Arrangement 16,765 — 16,765 — 119,366 — 102,601 16,765 Total 81,129 — 27,004 54,125 189,557 — 106,687 82,870 Total intangible assets 235,725 19,680 35,192 180,853 $ 347,592 $ 12,077 $ 106,687 $ 228,828
Schedule of Future Amortization Expenses for Intangible Assets	Amortization expenses for intangibles was $2,765 and $7,603 for the three and nine months ended September 30, 2020 (2019 – $2,529 and $6,131). Expected future amortization expenses for intangible assets as at September 30, 2020 are as follows: Year ending December 31, Amortization 2020 (remaining three months) $ 2,522 2021 9,801 2022 9,306 2023 9,078 2024 9,078 Thereafter 86,943 Total $ 126,728

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following items: September 30, 2020 December 31, 2019 Accrued interest on convertible notes $ 11,875 $ 5,938 Accrued payroll and employment related withholding taxes 10,709 24,765 Other accrued expenses and current liabilities 8,031 17,032 ABG finance liability - current 1,125 1,500 Accrued interest on Senior Facility 422 — Accrued legal and professional fees 364 1,174 Contingent consideration for acquisitions — 420 Total accrued expenses and other current liabilities $ 32,526 $ 50,829
Schedule of Reconciliation of Severance Costs Within Accrued Payroll Related to Scheduled Benefit Payments	The following table shows the reconciliation of the severance costs included within the accrued payroll and employment related withholding taxes balance above, relating to scheduled benefit payments which were communicated to employees prior to September 30, 2020: Opening Balance as of January 1, 2020 $ — Additional charges 3,575 Less payments made to employees (3,393 ) Closing Balance as of September 30, 2020 $ 182

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Components of Net Carrying Amount of Convertible Notes	The following table sets forth the net carrying amount of the convertible notes: September 30, 2020 December 31, 2019 5.00% Convertible Notes $ 475,000 $ 475,000 Unamortized discount (28,133 ) (34,219 ) Unamortized transaction costs (8,713 ) (10,571 ) Net carrying amount $ 438,154 $ 430,210
Schedule of Interest Expenses	The following table sets forth total interest expense recognized related to the convertible notes: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Contractual coupon interest $ 5,938 $ 5,938 $ 17,813 $ 17,813 Amortization of discount 2,059 1,969 6,087 5,790 Amortization of transaction costs 641 614 1,857 1,826 Total $ 8,638 $ 8,521 $ 25,757 $ 25,429

Senior Facility (Tables)

Senior Facility (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Instrument [Line Items]
Schedule of Components of Net Carrying Amount of Senior Facility	The following table sets forth the net carrying amount of the Senior Facility: September 30, 2020 Senior Facility $ 48,299 Unamortized transaction costs (2,355 ) Net carrying amount $ 45,944 Less: current portion of Senior Facility — Total noncurrent portion of Senior Facility $ 45,944
Schedule of Interest Expenses	The following table sets forth total interest expense recognized related to the convertible notes: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Contractual coupon interest $ 5,938 $ 5,938 $ 17,813 $ 17,813 Amortization of discount 2,059 1,969 6,087 5,790 Amortization of transaction costs 641 614 1,857 1,826 Total $ 8,638 $ 8,521 $ 25,757 $ 25,429
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Schedule of Interest Expenses	The following table sets forth total interest expense recognized related to the Senior Facility: Three months ended September 30, 2020 Nine months ended September 30, 2020 Contractual interest at Canadian prime plus 8.05% $ 1,260 $ 2,970 Amortization of transaction costs 407 943 Total $ 1,667 $ 3,913

Registered Offering and Warra_2

Registered Offering and Warrants (Tables)	9 Months Ended
	Sep. 30, 2020
Class Of Stock [Line Items]
Schedule of Pre-funded Warrants and Warrants Outstanding	Pre-funded warrants and warrants outstanding at September 30, 2020, and related activity for the nine months ended September 30, 2020 is as follows (reflects the number of shares of Class 2 common stock as if the warrants were converted to Class 2 common stock): Description Classification Exercise price Expiration date Balance December 31, 2019 Issued Exercised Balance September 30, 2020 Pre-Funded Warrants Liability $ 0.0001 March 17, 2025 — 11,750,000 (11,750,000 ) — Warrants Liability $ 5.95 March 17, 2025 — 19,000,000 — 19,000,000 Total — 30,750,000 (11,750,000 ) 19,000,000
Schedule of Estimated Fair Value of Warrant Liability	Quantitative information about Level 3 fair value measurements Fair value at September 30, 2020 Valuation technique Unobservable input Range (weighted average) Discount rate 16.5% Debt securities classified as available-for-sale $ 4,921 Discounted cash flow Probability of conversion/ prepayment nil Probability of default nil Warrant liability $ (71,636 ) Monte Carlo Volatility 100% Expected life 0.2 years to 5 years (2.4 years)
Warrant [Member]
Class Of Stock [Line Items]
Schedule of Estimated Fair Value of Warrant Liability	The Company estimated the fair value of the Warrant liability at September 30, 2020 at $3.76 per warrant using the Monte Carlo pricing model (Level 3) with the following weighted-average assumptions: Risk-free interest rate 0.35 % Expected volatility 100 % Expected term 5 years Expected dividend yield 0 % Strike price $ 5.95 Fair value of common stock $ 4.85

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Summary of Capital Stock	The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of September 30, 2020. The liquidation and dividend rights are identical among Class 1 common stock and Class 2 common stock, and all classes of common stock share equally in the Company’s earnings and losses. Par Value Authorized Voting Rights Class 1 common stock $ 0.0001 233,333,333 10 votes for each share Class 2 common stock $ 0.0001 500,000,000 1 vote for each share Preferred stock $ 0.0001 10,000,000 N/A

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Original Stock Option Plan [Member]
Schedule of Stock Option Activity	Stock option activity under the Original Plan is as follows: Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 3,014,004 $ 3.04 5.8 $ 44,108 Exercised (528,261 ) 1.15 Forfeited (62,153 ) 4.44 Cancelled (125,999 ) 3.30 Balance September 30, 2020 2,297,591 $ 3.38 3.8 $ 32,717 Vested and expected to vest, September 30, 2020 2,299,283 $ 3.37 3.8 $ 32,742 Vested and exercisable, September 30, 2020 2,198,632 $ 3.22 3.7 $ 31,750
2018 Equity Incentive Plan [Member] | Time-based Stock Options [Member]
Schedule of Stock Option Activity	Time-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 5,307,130 $ 14.04 8.4 $ 44,297 Granted — — Exercised (286,948 ) 7.76 Forfeited (245,222 ) 13.93 Cancelled (193,127 ) 13.11 Balance September 30, 2020 4,581,833 $ 14.48 7.6 $ — Vested and expected to vest, September 30, 2020 4,511,481 $ 14.32 7.5 $ — Vested and exercisable, September 30, 2020 3,276,183 $ 12.47 7.6 $ —
2018 Equity Incentive Plan [Member] | Performance-based Stock Options [Member]
Schedule of Stock Option Activity	Performance-based stock option activity Stock options Weighted- average exercise price Weighted- average remaining contractual term (years) Aggregate intrinsic value Balance December 31, 2019 520,000 $ 7.76 8.4 $ 4,872 Granted — — — Exercised (320,000 ) 7.76 Forfeited — — — Cancelled — — — Balance September 30, 2020 200,000 $ 7.76 7.6 $ — Vested and expected to vest, September 30, 2020 200,000 $ 7.76 7.6 $ — Vested and exercisable, September 30, 2020 200,000 $ 7.76 7.6 $ —
2018 Equity Incentive Plan [Member] | Time-based RSU [Member]
Schedule of RSU Activity	Time-based RSU activity Time-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 1,423,392 $ 42.05 Granted 2,024,334 8.67 Vested (396,051 ) 45.32 Forfeited (785,641 ) 27.88 Cancelled (17,711 ) 31.31 Non-vested September 30, 2020 2,248,323 $ 16.46
2018 Equity Incentive Plan [Member] | Performance-based RSUs [Member]
Schedule of RSU Activity	Performance-based RSUs activity Performance-based RSUs Weighted-average grant-date fair value per share Non-vested December 31, 2019 265,625 $ 7.76 Granted 448,230 7.05 Vested (159,375 ) 7.76 Non-vested September 30, 2020 554,480 $ 7.19

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (AOCI) (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	The components of AOCI, net of tax, were as follows: Foreign Currency Translation Adjustments Unrealized (loss) gain on available-for-sale debt securities Total Balance as at December 31, 2019 $ 10,021 $ (302 ) $ 9,719 Other comprehensive loss: Change in foreign currency translation (16,633 ) — (16,633 ) Change in unrealized (losses)/ gains on available-for-sale debt securities — (74 ) (74 ) Balance as at March 31, 2020 $ (6,612 ) $ (376 ) $ (6,988 ) Other comprehensive loss: Change in foreign currency translation 7,184 — 7,184 Change in unrealized gains on available-for-sale debt securities — 35 35 Balance as at June 30, 2020 $ 572 $ (341 ) $ 231 Other comprehensive loss: Change in foreign currency translation 2,265 — 2,265 Change in unrealized gains on available-for-sale debt securities — 193 193 Balance as at September 30, 2020 $ 2,837 $ (148 ) $ 2,689

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Maturities of Lease Liabilities	Maturities of lease liabilities: Year ending December 31, Operating Leases Finance Leases 2020 (remaining three months) $ 941 $ 235 2021 3,576 950 2022 3,019 5,389 2023 2,911 11,128 2024 2,489 — Thereafter 8,049 — Total lease payments $ 20,985 $ 17,702 Imputed interest 2,175 3,207 Obligations recognized $ 18,810 $ 14,495
Schedule of Future Non-cancellable Minimum Purchase Commitments	The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of September 30, 2020: Total 2020 (remaining three months) 2021 2022 2023 2024 Thereafter Purchase commitments $ 99,993 $ 69,732 $ 30,185 $ 38 $ 38 $ — $ — Total $ 99,993 $ 69,732 $ 30,185 $ 38 $ 38 $ — $ —
Schedule of Other Commitments Maturities	Total 2020 (remaining three months) 2021 2022 2023 2024 Thereafter ABG finance liability $ 7,500 $ — $ 1,500 $ 1,500 $ 1,500 $ 1,500 $ 1,500 Convertible notes, principal and interest 546,251 5,938 23,750 23,750 492,813 — — Senior Facility, principal and interest 55,483 1,268 5,071 49,144 — — — Portugal construction commitments 4,927 4,927 Total $ 614,161 $ 12,133 $ 30,321 $ 74,394 $ 494,313 $ 1,500 $ 1,500

General and Administrative Ex_2

General and Administrative Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
General And Administrative Expense [Abstract]
Schedule of General and Administrative Expenses	General and administrative expenses are comprised of the following items: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Salaries $ 8,323 $ 8,637 $ 24,365 $ 22,289 Other expenses 2,367 4,261 12,803 10,651 Professional fees 1,407 6,051 9,750 12,716 Loss on disposal of property and equipment 457 — 885 112 Travel expenses 132 1,448 939 3,330 Credit loss (recovery) expenses (21 ) (275 ) 288 520 Total $ 12,665 $ 20,122 $ 49,030 $ 49,618

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Nine months ended September 30, 2020 2019 Cash paid for interest $ 10,367 $ 17,613 Cash paid for income taxes $ 272 $ — Non-cash investing Acquisition of Manitoba Harvest $ — $ 157,917 Acquisition of Natura $ — $ 38,980 Investment in ABG Profit Participation Arrangement, net of receivable $ — $ 94,805 Purchases of investments and S&S acquisition $ — $ 14,508
Summary of Supplemental Cash Flow Information Related to Leases	Nine months ended September 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,672 $ 1,524 Operating cash flows from finance leases $ 445 $ — Financing cash flows from finance leases $ 309 $ — Non-cash additions to Right-of-use assets and lease liabilities Operating leases $ 423 $ 14,897 Finance leases $ — $ —

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring and Non-recurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total As of September 30, 2020 Investments Equity investments measured at fair value $ 2,207 $ — $ — $ 2,207 Debt securities classified as available-for-sale 844 — 4,921 5,765 Warrant liability — — (71,636 ) (71,636 ) Total recurring fair value measurements $ 3,051 $ — $ (66,715 ) $ (63,664 ) Quoted prices in active markets for Other Significant identical observable unobservable assets inputs inputs (Level 1) (Level 2) (Level 3) Total As of December 31, 2019 Investments Equity investments measured at fair value $ 4,183 $ — $ — $ 4,183 Debt securities classified as available-for-sale 727 — 4,320 5,047 Acquisition-related contingent consideration — — (420 ) (420 ) Total recurring fair value measurements $ 4,910 $ — $ 3,900 $ 8,810
Schedule of Opening Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis are Reconciled to Closing Balances	The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows: Debt securities classified as available-for- sale Warrant liability Opening balance as at December 31, 2019 $ 4,320 $ — Additions and settlements Additions — (69,414 ) Exercise — 49,053 Total gains or losses for the period: — — Included in net loss — — Interest expenses, net 601 — Change in fair value of warrant liability — (51,275 ) Impairment of assets — — Foreign currency translation loss, net — — Closing balance as at September 30, 2020 $ 4,921 $ (71,636 )
Schedule of Estimated Fair Value of Warrant Liability	Quantitative information about Level 3 fair value measurements Fair value at September 30, 2020 Valuation technique Unobservable input Range (weighted average) Discount rate 16.5% Debt securities classified as available-for-sale $ 4,921 Discounted cash flow Probability of conversion/ prepayment nil Probability of default nil Warrant liability $ (71,636 ) Monte Carlo Volatility 100% Expected life 0.2 years to 5 years (2.4 years)

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Summary of Revenue and Gross Profit	The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and gross profit as the measure of segment profit or loss. The accounting policies of each segment are the same as those set out under the summary of significant accounting policies in Note 1. There are no intersegment sales or transfers. The comparative three and nine months ended September 30, 2019 have been recast to reflect to the current segment structure. Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Revenue Gross profit / (loss) Revenue Gross profit Revenue Gross profit / (loss) Revenue Gross profit Cannabis $ 31,426 $ (4,717 ) $ 35,451 $ 9,225 $ 92,373 $ (13,863 ) $ 78,876 $ 16,213 Hemp $ 19,980 $ 8,456 $ 15,650 $ 6,628 $ 61,549 $ 23,053 $ 41,167 $ 17,298 Total $ 51,406 $ 3,739 $ 51,101 $ 15,853 $ 153,922 $ 9,190 $ 120,043 $ 33,511 No asset information is provided for the segments because the Company’s chief operating decision maker does not review this information by segment on a regular basis. Total revenue and gross profit for the reportable segments is equal to the Company’s consolidated revenue and gross profit. Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Gross profit for the segments $ 3,739 $ 15,853 $ 9,190 $ 33,511 General and administrative expenses 12,665 20,122 49,030 49,618 Sales and marketing expenses 10,000 16,974 40,709 39,161 Research and development expenses 921 2,315 2,831 4,891 Depreciation and amortization expenses 3,425 3,200 10,353 7,457 Stock-based compensation expenses 8,080 8,644 23,404 22,303 Impairment of assets — — 58,210 — Acquisition-related expenses (income), net — (13,454 ) — (6,566 ) Loss from equity method investments 1,420 1,837 4,495 1,837 Foreign exchange (gain) loss, net (9,319 ) 2,585 5,424 1,153 Change in fair value of warrant liability (31,913 ) — 51,275 — Interest expenses, net 10,437 8,680 30,147 26,005 Finance income from ABG — (210 ) — (557 ) Other expense (income), net (38 ) (1,116 ) 4,944 (6,185 ) Loss before income taxes $ (1,939 ) $ (33,724 ) $ (271,632 ) $ (105,606 ) Sources of revenue were as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Dried cannabis $ 21,079 $ 29,412 $ 61,339 $ 62,214 Cannabis extracts 10,239 5,819 30,246 16,172 Hemp products 19,980 15,650 61,549 41,167 Accessories and other 108 220 788 490 Total $ 51,406 $ 51,101 $ 153,922 $ 120,043 Channels of revenue were as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Cannabis Adult-use $ 19,926 $ 15,835 $ 58,466 $ 38,758 Canada - medical 3,399 3,898 11,285 9,222 International - medical 8,101 5,708 22,220 9,370 Bulk — 10,010 402 21,526 Total Cannabis revenue $ 31,426 $ 35,451 $ 92,373 $ 78,876 Hemp 19,980 15,650 61,549 41,167 Total $ 51,406 $ 51,101 $ 153,922 $ 120,043
Summary of Revenue Attributed to a Geographic Region Based on the Location of the Customer	Revenue attributed to geographic region based on the location of the customer was as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Canada $ 29,475 $ 33,585 $ 86,807 $ 81,138 United States 13,340 10,836 43,851 28,407 Other countries 8,591 6,680 23,264 10,498 Total $ 51,406 $ 51,101 $ 153,922 $ 120,043
Summary of Long-lived Assets Consisting of Property and Equipment, Net of Accumulated Depreciation, Attributed to Geographic Regions Based on their Physical Location	Long-lived assets consisting of property and equipment, net of accumulated depreciation, attributed to geographic regions based on their physical location were as follows: September 30, 2020 December 31, 2019 Canada $ 115,711 $ 144,065 Portugal 67,198 36,908 United States 4,659 3,171 Other countries 62 73 Total $ 187,630 $ 184,217

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Mar. 17, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Feb. 28, 2020	Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Net loss		$ (2,316,000)	$ (81,687,000)	$ (184,123,000)	$ (36,351,000)	$ (36,301,000)	$ (29,369,000)	$ (268,124,000)	$ (102,021,000)
Net cash used in operating activities								(104,486,000)	$ (167,255,000)
Working capital		171,349,000						171,349,000			$ 166,600,000
Proceeds from issuance of registered offering, net of issuance costs	$ 85,289,000							$ 85,465,000
Proceeds from registered equity offering, gross	$ 90,439,000	$ 46,153,000
Warrants issued	19,000,000
Warrants outstanding		19,000,000						19,000,000
Maximum allowed aggregate gross proceeds from share issuance under ATM program								$ 20,000,000
Warrant exercise price		$ 5.95						$ 5.95
Maximum amount of share issuance allowed per quarter								$ 6,000,000
Sale price		$ 5.95						$ 5.95
Cash and cash equivalents		$ 155,205,000						$ 155,205,000			$ 96,791,000
Antidilutive securities excluded from computation of earnings per share								13,141,298	8,043,920
Convertible Senior Notes Due 2023 [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument interest rate		5.00%						5.00%
Senior Facility [Member]
Summary Of Significant Accounting Policies [Line Items]
Maximum aggregate principal amount										$ 59,600,000
Aggregate principal amount borrowed										49,700,000
Additional draw provided		$ 9,900,000						$ 9,900,000		$ 9,900,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Impact to Statements of Net Loss and Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net (loss) income	$ (2,316)	$ (81,687)	$ (184,123)	$ (36,351)	$ (36,301)	$ (29,369)	$ (268,124)	$ (102,021)
Other comprehensive (loss) income	$ 2,458	$ 7,219	$ (16,707)	(4,852)	$ 2,974	$ (456)	$ (7,030)	(2,334)
Unadjusted [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net (loss) income				(35,678)				(101,032)
Other comprehensive (loss) income				(5,164)				(2,069)
Impact of Adoption [Member] | ASU 2016-01 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net (loss) income				(312)				265
Other comprehensive (loss) income				312				(265)
Impact of Adoption [Member] | ASC 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net (loss) income				(32)				(157)
Impact of Adoption [Member] | ASU 2018-07 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net (loss) income				$ (329)				$ (1,097)

Assets Held for Sale - Addition

Assets Held for Sale - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Indefinite-lived intangible asset, Impairment	$ 27,004	$ 106,687
Cultivation License [Member]
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Indefinite-lived intangible asset, Impairment	10,239
High Park Gardens Facility [Member] | Cannabis Reportable Segment [Member]
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Impairment charges of assets classified as held for sale	25,051
Impairment charge of land and building	13,616
Impairment charge on foreign currency translation adjustments	1,196
High Park Gardens Facility [Member] | Cannabis Reportable Segment [Member] | Cultivation License [Member]
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Indefinite-lived intangible asset, Impairment	$ 10,239

Assets Held for Sale - Summary

Assets Held for Sale - Summary of Assets and Liabilities Comprising Disposal Group Classified as Held for Sale (Detail) - High Park Gardens Facility [Member] - Cannabis Reportable Segment [Member] $ in Thousands	Sep. 30, 2020USD ($)
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Assets classified as held for sale	$ 6,797
Land and Buildings [Member]
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Assets classified as held for sale	$ 6,797

Assets Held for Sale - Summar_2

Assets Held for Sale - Summary of Pretax (Loss) Income Continuing Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Assets Of Disposal Group Including Discontinued Operation [Abstract]
Pre-tax (loss) income	$ (642)	$ 119	$ (28,335)	$ (396)

ABG Profit Participation Arra_2

ABG Profit Participation Arrangement - Additional Information (Detail) - USD ($)	Jan. 01, 2021	Jul. 01, 2020	Jan. 24, 2020	Jan. 01, 2020	Oct. 01, 2019	Apr. 01, 2019	Jan. 31, 2020	Sep. 30, 2019
Class Of Stock [Line Items]
Obligation to pay the additional consideration								$ (17,019,000)
A And R Profit Participation Agreement [Member]
Class Of Stock [Line Items]
Finance receivables write-offs through impairment of assets							$ 7,011,000
Finance receivable write-off through accumulated deficit							$ 28,900,000
ABG Intermediate Holdings Two LLC [Member] | A And R Profit Participation Agreement [Member]
Class Of Stock [Line Items]
Minimum participation rights with respect to each contract year			$ 10,000,000
ABG Prince Agreement [Member] | Scenario Forecast [Member]
Class Of Stock [Line Items]
Quarterly royalty payment in 2021, until maturity in 2025	$ 375,000
Class 2 Common Stock [Member] | ABG Intermediate Holdings Two LLC [Member] | A And R Profit Participation Agreement [Member]
Class Of Stock [Line Items]
Obligation to pay the additional consideration			$ (83,333,000)
Minimum [Member] | ABG Intermediate Holdings Two LLC [Member] | A And R Profit Participation Agreement [Member]
Class Of Stock [Line Items]
Percentage of participation rights			49.00%
Minimum [Member] | ABG Prince Agreement [Member]
Class Of Stock [Line Items]
Guaranteed minimum royalty payment		$ 500,000		$ 500,000	$ 500,000	$ 500,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 15,338	$ 15,926
Work-in-process	59,863	53,973
Finished goods	14,716	17,962
Total Inventory	$ 89,917	$ 87,861

Inventory - Schedule of Inven_2

Inventory - Schedule of Inventory Valuation Adjustments Included in Cost of Sales (Detail) - Inventory Valuation and Obsolescence [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Inventory [Line Items]
Inventory valuation adjustments	$ 13,443	$ 201	$ 36,116	$ 726
Raw Materials [Member]
Inventory [Line Items]
Inventory valuation adjustments	173		384
Work In Process [Member]
Inventory [Line Items]
Inventory valuation adjustments	11,164	$ 201	30,656	$ 726
Finished Goods [Member]
Inventory [Line Items]
Inventory valuation adjustments	$ 2,106		$ 5,076

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Cannabis [Member]
Inventory [Line Items]
Inventory write-downs	$ 13,318	$ 124	$ 31,626	$ 610
Hemp [Member]
Inventory [Line Items]
Inventory write-downs	125	77	4,490	116
Inventory Valuation Adjustments [Member]
Inventory [Line Items]
Cost of sales	13,443	$ 201	36,116	$ 726
Inventory Valuation Adjustments [Member] | Termination of Supply Agreement [Member]
Inventory [Line Items]
Cost of sales	5,157		10,090
Inventory Valuation Adjustments [Member] | Secure Supply [Member]
Inventory [Line Items]
Cost of sales	4,934		4,934
Inventory Valuation Adjustments [Member] | Additional Termination Penalties [Member]
Inventory [Line Items]
Cost of sales	$ 5,157		5,157
Inventory Valuation Adjustments [Member] | High Park Gardens Facility [Member]
Inventory [Line Items]
Cost of sales			$ 1,800

Prepayments and Other Current_3

Prepayments and Other Current Assets - Schedule of Prepayments and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Deposits	$ 15,325	$ 25,490
Prepayments	6,854	5,847
Taxes receivable	5,975	6,165
ABG finance receivable - current		671
Total	$ 28,154	$ 38,173

Prepayments and Other Current_4

Prepayments and Other Current Assets - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Cannabis [Member]
Prepayments And Other Assets Current [Line Items]
Write off Deposits	$ 4,934

Investments - Summary of Long-t

Investments - Summary of Long-term Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Equity investments at fair value	$ 2,207	$ 4,183
Equity investments under measurement alternative	14,738	14,954
Debt securities classified under available-for-sale method	5,765	5,047
Total other investments	$ 22,710	$ 24,184

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Unrealized gains (losses) on equity Investments	$ (506,000)	$ (274,000)	$ (1,272,000)	$ 264,000
Impairments or adjustments equity investments under measurement alternative	0	0	0	0
Credit loss expenses	(21,000)	(275,000)	288,000	520,000
Investment in joint venture under the equity method	8,911,000		8,911,000		$ 11,448,000
Fluent [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	5,147,000		5,147,000		7,836,000
Fluent [Member] | Joint Venture [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	2,323,000	10,090,000	2,323,000	10,090,000
Total fees charged			3,109,000	0
Fluent [Member] | Joint Venture [Member] | Accounts Receivable [Member]
Schedule Of Available For Sale Securities [Line Items]
Total fees charged					388,000
Fluent [Member] | Joint Venture [Member] | Accounts Payable [Member]
Schedule Of Available For Sale Securities [Line Items]
Total fees charged			441,000
Cannfections [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	3,764,000		3,764,000		3,612,000
Cannfections [Member] | Joint Venture [Member]
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	0	3,600,000	0	3,600,000
Investment in Equities [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, allowance for credit loss	0		0		0
Credit loss expenses	0	$ 0	0	$ 0
Long-term Investments [Member] | Investment in Equities [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, Gross unrealized loss	$ 148,000		$ 148,000		$ 302,000
Convertible Debt Instrument [Member]
Schedule Of Available For Sale Securities [Line Items]
Convertible debt instruments contractual maturity			2022

Investments - Summary of Owners

Investments - Summary of Ownership Interests in Equity Method Investments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Carrying value	$ 8,911		$ 8,911		$ 11,448
Gain (loss) from equity method investments	$ (1,420)	$ (1,837)	$ (4,495)	$ (1,837)
Fluent [Member]
Schedule Of Equity Method Investments [Line Items]
Approximate ownership %	50.00%		50.00%		50.00%
Carrying value	$ 5,147		$ 5,147		$ 7,836
Gain (loss) from equity method investments			$ (4,725)	$ (1,837)
Cannfections [Member]
Schedule Of Equity Method Investments [Line Items]
Approximate ownership %	50.00%		50.00%		50.00%
Carrying value	$ 3,764		$ 3,764		$ 3,612
Gain (loss) from equity method investments			$ 230

Investments - Summary of Financ

Investments - Summary of Financial Information for Equity Method Investments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 304,878		$ 304,878		$ 259,027
Current liabilities	133,529		133,529		92,427
Gross profit	3,739	$ 15,853	9,190	$ 33,511
Equity Method Investments [Member]
Schedule Of Equity Method Investments [Line Items]
Revenue			4,854
Gross profit			2,032
Net loss			(8,991)	$ (3,160)
Equity Method Investments [Member] | Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]
Schedule Of Equity Method Investments [Line Items]
Current assets	12,346		12,346		13,942
Noncurrent assets	5,205		5,205		4,987
Current liabilities	$ 4,965		$ 4,965		$ 1,561

Allowance for Credit Losses - S

Allowance for Credit Losses - Schedule of Allowance for Credit Losses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Allowance For Credit Loss [Abstract]
Allowance for credit losses, January 1, 2020			$ 615
Provision for expected credit losses	$ (21)	$ (275)	288	$ 520
Write-offs charged against allowance			(74)
Foreign currency translation adjustment			(3)
Allowance for credit losses, September 30, 2020	826		826
Accounts receivable balance before allowance for credit losses and provision for sales returns, September 30, 2020	$ 26,843		$ 26,843

Allowance for Credit Losses - A

Allowance for Credit Losses - Additional Information (Detail)	Sep. 30, 2020InvestmentHolding
Allowance For Credit Loss [Abstract]
Number of available for sale debt securities	2
Number of available for sale securities in unrealized loss position	1

Allowance for Credit Losses -_2

Allowance for Credit Losses - Schedule of Fair Value and Unrealized Loss of Investment (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Fair value	$ 1,124	$ 945
Unrealized loss	$ 148	$ 302

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 211,754	$ 201,334
Less: accumulated depreciation	(24,124)	(17,117)
Total	187,630	184,217
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,488	6,417
Buildings and Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	108,021	109,172
Laboratory and Manufacturing Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	34,500	31,173
Office and Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,779	2,659
Right-of-Use Assets under Finance Lease [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	14,415	14,753
Construction-in-Process, Not Yet Available for Use [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 46,551	$ 37,160

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
High Park Gardens Facility [Member]
Property Plant And Equipment [Line Items]
Non-cash impairment charges	$ 13,616

Goodwill - Schedule of Change i

Goodwill - Schedule of Change in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Goodwill [Line Items]
Balance as of December 31, 2019	$ 163,251
Foreign currency translation adjustment	(3,656)
Balance as of September 30, 2020	159,595
Hemp [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	133,314
Foreign currency translation adjustment	(2,971)
Balance as of September 30, 2020	130,343
Cannabis [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	29,937
Foreign currency translation adjustment	(685)
Balance as of September 30, 2020	$ 29,252

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Goodwill [Line Items]
Goodwill	$ 159,595,000	$ 159,595,000	$ 163,251,000
Goodwill, impaired, facts and circumstances leading to impairment		A relatively small change in the underlying assumptions, including a 1% change in the weighted average cost of capital, continued lack of clarity from the Food and Drug Administration regarding approval of CBD, or the financial performance of the reporting unit in future years, may cause a change in the results of the impairment assessment in future periods and, as such, could result in an impairment of goodwill.
Hemp Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	$ 130,343,000
Reporting unit, percentage of fair value in excess of carrying amount	26.00%
Reporting unit, amount of fair value in excess of carrying amount	$ 76,998,000
Goodwill impairment loss	$ 0
Hemp Reporting Unit [Member] | Minimum [Member]
Goodwill [Line Items]
Weighted average cost of capital discount rate	10.00%
Hemp Reporting Unit [Member] | Minimum [Member] | Revenue and Expense Growth Assumptions [Member]
Goodwill [Line Items]
Reporting unit, percentage of fair value in excess of carrying amount	9.00%
Hemp Reporting Unit [Member] | Maximum [Member]
Goodwill [Line Items]
Weighted average cost of capital discount rate	12.00%
Hemp Reporting Unit [Member] | Maximum [Member] | Revenue and Expense Growth Assumptions [Member]
Goodwill [Line Items]
Reporting unit, percentage of fair value in excess of carrying amount	38.00%

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	$ 154,596	$ 158,035
Definite-lived intangible asset, Accumulated Amortization	19,680	12,077
Definite-lived intangible asset, Impairment	8,188
Definite-lived intangible asset, Net	126,728	145,958
Indefinite-lived intangible asset, Cost	81,129	189,557
Indefinite-lived intangible asset, Impairment	27,004	106,687
Indefinite-lived intangible asset, Net	54,125	82,870
Total intangible asset, Cost	235,725	347,592
Total intangible asset, Impairment	35,192	106,687
Total intangible asset, Net	180,853	228,828
Patents [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	669	716
Definite-lived intangible asset, Accumulated Amortization	131	99
Definite-lived intangible asset, Impairment	538
Definite-lived intangible asset, Net		617
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	132,837	135,953
Definite-lived intangible asset, Accumulated Amortization	13,241	7,132
Definite-lived intangible asset, Net	119,596	128,821
Developed Technology [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	6,912	7,074
Definite-lived intangible asset, Accumulated Amortization	1,094	590
Definite-lived intangible asset, Net	5,818	6,484
Websites [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	5,126	5,157
Definite-lived intangible asset, Accumulated Amortization	3,921	3,331
Definite-lived intangible asset, Net	1,205	1,826
Trademarks and Licenses [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Definite-lived intangible asset, Cost	9,052	9,135
Definite-lived intangible asset, Accumulated Amortization	1,293	925
Definite-lived intangible asset, Impairment	7,650
Definite-lived intangible asset, Net	109	8,210
Cultivation License [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost	10,239	10,689
Indefinite-lived intangible asset, Impairment	10,239
Indefinite-lived intangible asset, Net		10,689
Alef License [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost		4,086
Indefinite-lived intangible asset, Impairment		4,086
Trademarks [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost	54,125	55,416
Indefinite-lived intangible asset, Net	54,125	55,416
Rights under ABG Profit Participation Arrangement [Member]
Finite and Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost	16,765	119,366
Indefinite-lived intangible asset, Impairment	$ 16,765	102,601
Indefinite-lived intangible asset, Net		$ 16,765

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Non-cash impairment charge of intangible assets				$ 27,004		$ 106,687
Non-cash impairment charge of intangible assets				8,188
Amortization expenses for intangible assets		$ 2,765	$ 2,529	7,603	$ 6,131
Separation from Smith & Sinclair [Member]
Finite Lived Intangible Assets [Line Items]
Additional non-cash impairment charges	$ 3,320
High Park Gardens Facility [Member]
Finite Lived Intangible Assets [Line Items]
Non-cash impairment charge of intangible assets				10,239
ABG Prince Agreement [Member]
Finite Lived Intangible Assets [Line Items]
Non-cash impairment charge of intangible assets				6,063
ABG Profit Participation Agreement [Member]
Finite Lived Intangible Assets [Line Items]
Non-cash impairment charge of intangible assets				$ 16,765
CBD Trademarks and Patents [Member] | Separation from Smith & Sinclair [Member]
Finite Lived Intangible Assets [Line Items]
Additional non-cash impairment charges	$ 2,126

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Future Amortization Expenses for Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2020 (remaining three months)	$ 2,522
2021	9,801
2022	9,306
2023	9,078
2024	9,078
Thereafter	86,943
Definite-lived intangible asset, Net	$ 126,728	$ 145,958

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Accrued interest on convertible notes	$ 11,875	$ 5,938
Accrued payroll and employment related withholding taxes	10,709	24,765
Other accrued expenses and current liabilities	8,031	17,032
Accrued interest on Senior Facility	422
Accrued legal and professional fees	364	1,174
Contingent consideration for acquisitions		420
Total accrued expenses and other current liabilities	32,526	50,829
ABG [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
ABG finance liability - current	$ 1,125	$ 1,500

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	$ 239	$ 0	$ 3,576	$ 0
Cannabis Reportable Segment [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	239		2,432
Hemp Reportable Segment [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	0		1,144
General and Administrative Expense [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	133		3,128
Cost of Sales [Member]
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Severance Costs	$ 106		$ 448

Accrued Expenses and Other Cu_5

Accrued Expenses and Other Current Liabilities - Schedule of Reconciliation of Severance Costs Within Accrued Payroll Related to Scheduled Benefit Payments (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Employee Related Liabilities Current [Abstract]
Additional charges	$ 3,575
Less payments made to employees	(3,393)
Severance costs,Closing Balance	$ 182

Convertible Notes - Additional

Convertible Notes - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Convertible Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 475,000	$ 475,000

Convertible Notes - Schedule of

Convertible Notes - Schedule of Components of Net Carrying Amount of Convertible Notes (Detail) - Convertible Senior Notes Due 2023 [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
5.00% Convertible Notes	$ 475,000	$ 475,000
Unamortized discount	(28,133)	(34,219)
Unamortized transaction costs	(8,713)	(10,571)
Net carrying amount	$ 438,154	$ 430,210

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Interest Expense Schedule of Interest Expense Related to Convertible Notes (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Amortization of discount			$ 7,944	$ 7,616
Convertible Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Contractual coupon interest	$ 5,938	$ 5,938	17,813	17,813
Amortization of discount	2,059	1,969	6,087	5,790
Amortization of transaction costs	641	614	1,857	1,826
Total	$ 8,638	$ 8,521	$ 25,757	$ 25,429

Senior Facility - Additional In

Senior Facility - Additional Information (Detail)	Jun. 05, 2020USD ($)	Jun. 05, 2020CAD ($)	Feb. 28, 2020USD ($)	Sep. 30, 2020	Jun. 29, 2020USD ($)	Jun. 29, 2020CAD ($)	Jun. 05, 2020CAD ($)	Feb. 28, 2020CAD ($)
Line of Credit Facility [Line Items]
Aggregate repayment amount	$ 47,355,000						$ 64,283,000
Canadian prime rate				8.05%
Senior Secured Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Withdrawal of outstanding request for additional draw	$ 9,900,000						$ 13,300,000
Canadian prime rate				8.05%
Senior Secured Term Loan Facility [Member] | High Park Holdings Ltd. [Member]
Line of Credit Facility [Line Items]
Maximum aggregate principal amount			$ 59,600,000					$ 79,800,000
Aggregate principal amount borrowed			49,700,000					66,500,000
Amount withdrawable on election			$ 9,900,000					13,300,000
Canadian prime rate			8.05%
Frequency of payment and payment terms			The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice.
Transaction fees incurred			$ 3,306,000					4,425,000
Debt instrument, face amount					$ 19,153,000	$ 26,000,000
Minimum unrestricted cash threshold for capital expenditures and investments			$ 29,466,000					$ 40,000,000
Senior Secured Term Loan Facility Amendment [Member]
Line of Credit Facility [Line Items]
Line of credit facility, expiration date	Feb. 28, 2022	Feb. 28, 2022
Additional proceeds available	$ 9,900,000	$ 13,300,000
Senior Secured Term Loan Facility Amendment [Member] | High Park Gardens Facility [Member]
Line of Credit Facility [Line Items]
Sales proceeds received by the lender	40.00%	40.00%
Sales proceeds retained by the borrower	60.00%	60.00%

Senior Facility - Schedule of C

Senior Facility - Schedule of Components of Net Carrying Amount of Senior Facility (Detail) - Senior Secured Term Loan Facility [Member] $ in Thousands	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Debt instrument, face amount	$ 48,299
Unamortized transaction costs	(2,355)
Net carrying amount	45,944
Total noncurrent portion of Senior Facility	$ 45,944

Senior Facility - Schedule of I

Senior Facility - Schedule of Interest Expenses Recognized Related to Senior Facility (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Amortization of discount on convertible notes		$ 7,944	$ 7,616
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Contractual interest at Canadian prime plus 8.05%	$ 1,260	2,970
Amortization of discount on convertible notes	407	943
Total	$ 1,667	$ 3,913

Senior Facility - Schedule of_2

Senior Facility - Schedule of Interest Expenses Recognized Related to Senior Facility (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2020
Debt Instrument [Line Items]
Canadian prime rate	8.05%
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Canadian prime rate	8.05%

Registered Offering and Warra_3

Registered Offering and Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 17, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020
Class Of Stock [Line Items]
Sale price		$ 5.95				$ 5.95
Warrants to purchase		19,000,000				19,000,000
Warrant exercise price		$ 5.95				$ 5.95
Shares issued for common stock at-the-market, net of issuance costs	$ 90,439	$ 45,230	$ 3,842	$ 27,027	$ 37,445
Issuance costs incurred on registered offering	$ 5,150
Daily cash penalty	1.00%
Level 3 [Member]
Class Of Stock [Line Items]
Estimated fair value of warrant liability per warrant		$ 3.76				3.76
Other Expense (Income) [Member]
Class Of Stock [Line Items]
Issuance costs incurred on registered offering	$ 3,953
Pre funded Warrants [Member]
Class Of Stock [Line Items]
Warrant exercise price		$ 0.0001				$ 0.0001
Warrant Liability [Member]
Class Of Stock [Line Items]
Shares issued for common stock at-the-market, net of issuance costs	$ 69,414
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Shares issued for common stock at-the-market, net of issuance costs, shares	7,250,000	6,781,090				9,493,494
Sale price	$ 4.76
Warrants to purchase	19,000,000
Warrant exercise price	$ 5.95
Shares issued for common stock at-the-market, net of issuance costs	$ 21,025
Issuance costs incurred on registered offering	$ 1,197					$ 1,540
Class 2 Common Stock [Member] | Minimum [Member]
Class Of Stock [Line Items]
Warrants expire period	6 months
Class 2 Common Stock [Member] | Maximum [Member]
Class Of Stock [Line Items]
Warrants expire period	5 years
Class 2 Common Stock [Member] | Pre funded Warrants [Member]
Class Of Stock [Line Items]
Sale price	$ 4.7599
Warrants to purchase	11,750,000			11,750,000
Warrant exercise price	$ 0.0001			$ 0.0001

Registered Offering and Warra_4

Registered Offering and Warrants - Schedule of Pre-funded Warrants and Warrants Outstanding (Detail)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrant exercise price | $ / shares	$ 5.95
Warrant issued	30,750,000
Warrant exercised	(11,750,000)
Ending Balance	19,000,000
Pre funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant description	Pre-Funded Warrants
Warrant classification	Liability
Warrant exercise price | $ / shares	$ 0.0001
Warrant expiration date	Mar. 17, 2025
Warrant issued	11,750,000
Warrant exercised	(11,750,000)
Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant description	Warrants
Warrant classification	Liability
Warrant exercise price | $ / shares	$ 5.95
Warrant expiration date	Mar. 17, 2025
Warrant issued	19,000,000
Ending Balance	19,000,000

Registered Offering and Warra_5

Registered Offering and Warrants - Schedule of Estimated Fair Value of Warrant Liability (Detail) - Warrant [Member] - Level 3 [Member]	Sep. 30, 2020USD ($)yr
Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0.0035
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	1
Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input | yr	5
Expected Dividend Yield [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0
Strike Price [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	5.95
Fair Value of Common Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	4.85

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Capital Stock (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 29, 2020
Class 1 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, par value	$ 0.0001
Common stock, shares authorized	233,333,333	250,000,000
Common stock voting rights	10 votes for each share
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, par value	$ 0.0001
Common stock, shares authorized	500,000,000
Common stock voting rights	1 vote for each share
Preferred Stock [Member]
Class Of Stock [Line Items]
Convertible preferred stock	$ 0.0001
Convertible preferred stock shares authorized	10,000,000
Convertible preferred stock voting rights	N/A

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Capital Stock (Parenthetical) (Detail)	Sep. 30, 2020Vote
Class 1 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, votes for each share	10
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Common stock, votes for each share	1

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Sep. 30, 2020	Mar. 17, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 29, 2020	Mar. 31, 2020
Class Of Stock [Line Items]
Warrant exercise price	$ 5.95		$ 5.95	$ 5.95
Warrants to purchase	19,000,000		19,000,000	19,000,000
Proceeds from issuance of common stock, gross		$ 90,439,000	$ 46,153,000
Transaction costs recorded net against allocated gross proceeds in additional paid-in-capital		$ 5,150,000
Maximum allowed aggregate gross proceeds from share issuance under ATM program				$ 20,000,000
Maximum amount of share issuance allowed per quarter				$ 6,000,000
Pre funded Warrants [Member]
Class Of Stock [Line Items]
Warrant exercise price	$ 0.0001		$ 0.0001	$ 0.0001
Class 2 Common Stock [Member]
Class Of Stock [Line Items]
Common stock issued, Shares		7,250,000	6,781,090	9,493,494
Warrant exercise price		$ 5.95
Warrants to purchase		19,000,000
Proceeds from issuance of common stock, gross			$ 46,153,000	$ 76,999,000
Transaction costs recorded net against allocated gross proceeds in additional paid-in-capital		$ 1,197,000		1,540,000
Maximum allowed aggregate gross proceeds from share issuance under ATM program				20,000,000
Maximum amount of share issuance allowed per quarter				$ 6,000,000
Common stock, shares authorized	500,000,000		500,000,000	500,000,000
Common stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Class 2 Common Stock [Member] | Pre funded Warrants [Member]
Class Of Stock [Line Items]
Warrant exercise price		$ 0.0001				$ 0.0001
Warrants to purchase		11,750,000				11,750,000
Class 1 Common Stock [Member]
Class Of Stock [Line Items]
Conversion of stock, shares converted	13,159,762
Common stock ceased to represent percentage of outstanding common stock	10.00%
Common stock, shares authorized	233,333,333		233,333,333	233,333,333	250,000,000
Common stock, shares retired	16,666,667		16,666,667	16,666,667
Common stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares outstanding	0		0	0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expenses	$ 375		$ 375
Unrecognized stock-based compensation expense to be recognized in period, years			9 months 18 days
Original Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expense	114	$ 143	$ 410	$ 411
Stock options granted			0	0
Fair values of stock option vested			$ 118		$ 2,789
2018 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expense	7,966	$ 8,501	22,994	$ 21,892
Unrecognized compensation expenses	$ 40,805		$ 40,805
Unrecognized stock-based compensation expense to be recognized in period, years			1 year 10 days
2018 Equity Incentive Plan [Member] | Time-based Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			0	10,000
Fair values of stock option vested			$ 31,299		16,708
Weighted average fair values of stock options granted, per share			$ 0	$ 12.01
2018 Equity Incentive Plan [Member] | Performance-based Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			0	0
Fair values of stock option vested			$ 0		$ 1,246
2018 Equity Incentive Plan [Member] | Time-based RSU [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs granted			2,024,334	944,616
Number of RSUs vested			396,051	54,635
2018 Equity Incentive Plan [Member] | Performance-based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs granted			448,230	0
Number of RSUs vested			159,375	731,250
2018 Equity Incentive Plan [Member] | Class 2 common stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for issuance, annual automatic increase percentage	4.00%		4.00%
2018 Equity Incentive Plan [Member] | Class 2 common stock [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock reserved for issuance, term			10 years
2018 Equity Incentive Plan [Member] | Class 2 common stock [Member] | Stock Options and Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares are reserved for issuance	17,037,421		17,037,421		12,926,172

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Original Stock Option Plan [Member]
Stock options
Shares, Beginning Balance	3,014,004
Shares, Granted	0	0
Shares, Exercised	(528,261)
Shares, Forfeited	(62,153)
Shares, Cancelled	(125,999)
Shares, Ending Balance	2,297,591		3,014,004
Shares, Vested and expected to vest	2,299,283
Shares, Vested and exercisable	2,198,632
Weighted-average exercise price
Weighted-average exercise price, Beginning Balance	$ 3.04
Weighted-average exercise price, Exercised	1.15
Weighted-average exercise price, Forfeited	4.44
Weighted-average exercise price, Cancelled	3.30
Weighted-average exercise price, Ending Balance	3.38		$ 3.04
Weighted-average exercise price, Vested and expected to vest	3.37
Weighted-average exercise price, Vested and exercisable	$ 3.22
Weighted-average remaining contractual term (years)
Weighted-average remaining contractual term	3 years 9 months 18 days		5 years 9 months 18 days
Weighted-average remaining contractual term, Vested and expected to vest	3 years 9 months 18 days
Weighted-average remaining contractual term, Vested and exercisable	3 years 8 months 12 days
Aggregate intrinsic value
Aggregate intrinsic value	$ 32,717		$ 44,108
Aggregate intrinsic value, Vested and expected to vest	32,742
Aggregate intrinsic value, Vested and exercisable	$ 31,750
2018 Equity Incentive Plan [Member] | Time-based Stock Options [Member]
Stock options
Shares, Beginning Balance	5,307,130
Shares, Granted	0	10,000
Shares, Exercised	(286,948)
Shares, Forfeited	(245,222)
Shares, Cancelled	(193,127)
Shares, Ending Balance	4,581,833		5,307,130
Shares, Vested and expected to vest	4,511,481
Shares, Vested and exercisable	3,276,183
Weighted-average exercise price
Weighted-average exercise price, Beginning Balance	$ 14.04
Weighted-average exercise price, Exercised	7.76
Weighted-average exercise price, Forfeited	13.93
Weighted-average exercise price, Cancelled	13.11
Weighted-average exercise price, Ending Balance	14.48		$ 14.04
Weighted-average exercise price, Vested and expected to vest	14.32
Weighted-average exercise price, Vested and exercisable	$ 12.47
Weighted-average remaining contractual term (years)
Weighted-average remaining contractual term	7 years 7 months 6 days		8 years 4 months 24 days
Weighted-average remaining contractual term, Vested and expected to vest	7 years 6 months
Weighted-average remaining contractual term, Vested and exercisable	7 years 7 months 6 days
Aggregate intrinsic value
Aggregate intrinsic value			$ 44,297
2018 Equity Incentive Plan [Member] | Performance-based Stock Options [Member]
Stock options
Shares, Beginning Balance	520,000
Shares, Granted	0	0
Shares, Exercised	(320,000)
Shares, Ending Balance	200,000		520,000
Shares, Vested and expected to vest	200,000
Shares, Vested and exercisable	200,000
Weighted-average exercise price
Weighted-average exercise price, Beginning Balance	$ 7.76
Weighted-average exercise price, Exercised	7.76
Weighted-average exercise price, Ending Balance	7.76		$ 7.76
Weighted-average exercise price, Vested and expected to vest	7.76
Weighted-average exercise price, Vested and exercisable	$ 7.76
Weighted-average remaining contractual term (years)
Weighted-average remaining contractual term	7 years 7 months 6 days		8 years 4 months 24 days
Weighted-average remaining contractual term, Vested and expected to vest	7 years 7 months 6 days
Weighted-average remaining contractual term, Vested and exercisable	7 years 7 months 6 days
Aggregate intrinsic value
Aggregate intrinsic value			$ 4,872

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of RSU Activity (Detail) - 2018 Equity Incentive Plan [Member] - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Time-based RSU [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share equivalent, Beginning Balance	1,423,392
Share equivalent, Granted	2,024,334	944,616
Share equivalent, Vested	(396,051)	(54,635)
Share equivalent, Forfeited	(785,641)
Share equivalent, Cancelled	(17,711)
Share equivalent, Ending Balance	2,248,323
Weighted-average grant date fair value, Beginning Balance	$ 42.05
Weighted-average grant date fair value, Granted	8.67
Weighted-average grant date fair value, Vested	45.32
Weighted-average grant date fair value, Forfeited	27.88
Weighted-average grant date fair value, Cancelled	31.31
Weighted-average grant date fair value, Ending Balance	$ 16.46
Performance-based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share equivalent, Beginning Balance	265,625
Share equivalent, Granted	448,230	0
Share equivalent, Vested	(159,375)	(731,250)
Share equivalent, Ending Balance	554,480
Weighted-average grant date fair value, Beginning Balance	$ 7.76
Weighted-average grant date fair value, Granted	7.05
Weighted-average grant date fair value, Vested	7.76
Weighted-average grant date fair value, Ending Balance	$ 7.19

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (AOCI) - Schedule of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 231	$ (6,988)	$ 9,719		$ 9,719
Change in foreign currency translation	2,265	7,184	(16,633)	$ (4,863)	(7,184)	$ (2,414)
Change in unrealized (losses)/ gains on available-for-sale debt securities	193	35	(74)
Ending balance	2,689	231	(6,988)		2,689
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	572	(6,612)	10,021		10,021
Change in foreign currency translation	2,265	7,184	(16,633)
Ending balance	2,837	572	(6,612)		2,837
Unrealized (Loss) Gain on Available-for-sale Debt Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(341)	(376)	(302)		(302)
Change in unrealized (losses)/ gains on available-for-sale debt securities	193	35	(74)
Ending balance	$ (148)	$ (341)	$ (376)		$ (148)

Commitments and Contingencies -

Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Operating leases
2020 (remaining three months)	$ 941
2021	3,576
2022	3,019
2023	2,911
2024	2,489
Thereafter	8,049
Total lease payments	20,985
Imputed interest	2,175
Obligations recognized	18,810
Finance leases
2020 (remaining three months)	235
2021	950
2022	5,389
2023	11,128
Total lease payments	17,702
Imputed interest	3,207
Obligations recognized	$ 14,495

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Non-cancellable Minimum Purchase Commitments (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Purchase Commitment Excluding Longterm Commitment [Line Items]
Total	$ 99,993
2020 (remaining three months)	69,732
2021	30,185
2022	38
2023	38
Purchase Commitments [Member]
Purchase Commitment Excluding Longterm Commitment [Line Items]
Total	99,993
2020 (remaining three months)	69,732
2021	30,185
2022	38
2023	$ 38

Commitments and Contingencies_3

Commitments and Contingencies - Additional Information (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2020USD ($)	Dec. 31, 2018USD ($)kg
Long Term Purchase Commitment [Line Items]
Estimated compensation fee	$ 10,350,000
Rose Lifescience, Inc [Member]
Long Term Purchase Commitment [Line Items]
Maximum quantity of purchase commitment | kg		2,000
Purchase commitment price based on cost of goods sold percentage		115.00%
Rose Lifescience, Inc [Member] | Cannabis [Member]
Long Term Purchase Commitment [Line Items]
Purchase commitment percentage		40.00%
Rose Lifescience, Inc [Member] | Distribution and Marketing [Member]
Long Term Purchase Commitment [Line Items]
Commitment Term		5 years
Rose Lifescience, Inc [Member] | Distribution and Marketing [Member] | Minimum [Member]
Long Term Purchase Commitment [Line Items]
Minimum commitment Fee		$ 384,000

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Other Commitments Maturities (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Other Commitments [Line Items]
Total	$ 614,161
2020 (remaining three months)	12,133
2021	30,321
2022	74,394
2023	494,313
2024	1,500
Thereafter	1,500
ABG Finance Liability [Member]
Other Commitments [Line Items]
Total	7,500
2021	1,500
2022	1,500
2023	1,500
2024	1,500
Thereafter	1,500
Convertible Notes, Principal and Interest [Member]
Other Commitments [Line Items]
Total	546,251
2020 (remaining three months)	5,938
2021	23,750
2022	23,750
2023	492,813
Senior Facility, Principal and Interest [Member]
Other Commitments [Line Items]
Total	55,483
2020 (remaining three months)	1,268
2021	5,071
2022	49,144
Portugal Construction Commitments [Member]
Other Commitments [Line Items]
Total	4,927
2020 (remaining three months)	$ 4,927

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Detail)	9 Months Ended
	Sep. 30, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Revenue From Contract With Customer [Abstract]
Number of reportable segments | Segment	2
Contract balances in the balance sheets | $	$ 0	$ 0

General and Administrative Ex_3

General and Administrative Expenses - Schedule of General and Administrative Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
General And Administrative Expense [Abstract]
Salaries	$ 8,323	$ 8,637	$ 24,365	$ 22,289
Other expenses	2,367	4,261	12,803	10,651
Professional fees	1,407	6,051	9,750	12,716
Loss on disposal of property and equipment	457		885	112
Travel expenses	132	1,448	939	3,330
Credit loss expenses	(21)	(275)	288	520
Total	$ 12,665	$ 20,122	$ 49,030	$ 49,618

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Noncash Or Part Noncash Acquisitions [Line Items]
Cash paid for interest	$ 10,367	$ 17,613
Cash paid for income taxes	$ 272
Manitoba Harvest [Member]
Non-cash investing
Acquisition of Manitoba Harvest, Natura		157,917
Natura [Member]
Non-cash investing
Acquisition of Manitoba Harvest, Natura		38,980
Investment In ABG [Member]
Non-cash investing
Investment in ABG Profit Participation Arrangement, net of receivable		94,805
Investments and S&S [Member]
Non-cash investing
Purchases of investments and S&S acquisition		$ 14,508

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,672	$ 1,524
Operating cash flows from finance leases	445
Financing cash flows from finance leases	309
Non-cash additions to Right-of-use assets and lease liabilities
Operating leases	$ 423	$ 14,897

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Annual lease payments	$ 20,985		$ 20,985
Accounts payable to related party	$ 141		$ 141		$ 68
Cannfections [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%		50.00%		50.00%
Fluent [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%		50.00%		50.00%
Ten Eleven [Member]
Related Party Transaction [Line Items]
Annual lease payments	$ 470		$ 470
Sub-leases expiration period			May 31, 2020
Joint Venture [Member] | Cannfections [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%		50.00%
Percentage of voting interest	50.00%		50.00%
Joint Venture [Member] | Fluent [Member]
Related Party Transaction [Line Items]
Percentage of ownership	50.00%		50.00%
Percentage of voting interest	50.00%		50.00%
General and Administrative Expense [Member] | Aircraft Time Share Reimbursement [Member]
Related Party Transaction [Line Items]
Payment for use of aircraft	$ 0	$ 0	$ 261	$ 0
General and Administrative Expense [Member] | Leafly Holdings, Inc [Member]
Related Party Transaction [Line Items]
Operational expenses	5	130	134	149
General and Administrative Expense [Member] | Docklight L L C
Related Party Transaction [Line Items]
Management service fees expense	$ 331	44	748	176
General and Administrative Expense [Member] | Ten Eleven [Member]
Related Party Transaction [Line Items]
Management service fees expense		75	71	200
Other Income, Net [Member] | Ten Eleven [Member]
Related Party Transaction [Line Items]
Sublease income		$ 115	$ 196	$ 192

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)
Financial Instruments [Abstract]
Change in exchange rate		10.00%
Carrying value of net asset		$ 23,578
Canadian prime rate		8.05%
Convertible notes, fixed interest rate	5.00%	5.00%
Change in Canadian prime rate		1.00%
Loss due to one percentage change in Canadian prime rate	$ 127	$ 295

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Assets Measured Fair Value on Recurring Basis (Detail) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Measurements, Recurring [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liability	$ (71,636)
Total recurring fair value measurements	(63,664,000)	$ 8,810,000
Acquisition-related contingent consideration		(420,000)
Fair Value, Measurements, Recurring [Member] | Equity Investments Measured at Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	2,207,000	4,183,000
Fair Value, Measurements, Recurring [Member] | Debt Securities Classified as Available-for-Sale [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	5,765,000	5,047,000
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total recurring fair value measurements	3,051,000	4,910,000
Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Equity Investments Measured at Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	2,207,000	4,183,000
Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Debt Securities Classified as Available-for-Sale [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	844,000	727,000
Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liability	(71,636)
Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liability	(71,636)
Total recurring fair value measurements	(66,715,000)	3,900,000
Acquisition-related contingent consideration		(420,000)
Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Debt Securities Classified as Available-for-Sale [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total investments	$ 4,921,000	$ 4,320,000

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Opening Balances of Assets and Liabilities Categorized Within Level 3 of the Fair Value Hierarchy Measured at Fair Value on a Recurring Basis (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Fair Value Disclosures [Abstract]
Debt securities classified as available-for-sale, Beginning Balance	$ 4,320
Debt securities classified as available-for-sale, Interest expenses, net	601
Debt securities classified as available-for-sale, Ending Balance	4,921
Warrant liability, Additions	(69,414)
Warrant liability, Exercise	49,053
Warrant liability, Change in fair value of warrant liability	(51,275)
Warrant liability, Ending Balance	$ (71,636)

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Quantitative Information about Level 3 Fair Value Measurements (Detail)	Sep. 30, 2020USD ($)yr	Dec. 31, 2019USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of, Debt securities classified as available-for-sale | $	$ 5,765,000	$ 5,047,000
Quantitative information about Level 3 Fair Value Measurements [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of, Debt securities classified as available-for-sale | $	$ 4,921,000
Debt Securities, Available-for-sale, Valuation Technique [Extensible List]	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Warrant liability | $	$ (71,636)
Warrants and Rights Outstanding, Valuation Technique [Extensible List]	tlry:ValuationTechniqueMonteCarloMember
Quantitative information about Level 3 Fair Value Measurements [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Debt securities classified as available-for-sale, Range	16.5
Quantitative information about Level 3 Fair Value Measurements [Member] | Probability of Conversion/ Prepayment [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Debt securities classified as available-for-sale, Range
Quantitative information about Level 3 Fair Value Measurements [Member] | Probability of Default [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Debt securities classified as available-for-sale, Range
Quantitative information about Level 3 Fair Value Measurements [Member] | Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input	100
Quantitative information about Level 3 Fair Value Measurements [Member] | Minimum [Member] | Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input | yr	0.2
Quantitative information about Level 3 Fair Value Measurements [Member] | Maximum [Member] | Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input | yr	5
Quantitative information about Level 3 Fair Value Measurements [Member] | Weighted Average [Member] | Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant and rights measurement input | yr	2.4

Business Segment Information -

Business Segment Information - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)Segment	Sep. 30, 2019USD ($)	Dec. 31, 2019
Segment Reporting Information [Line Items]
Number of operating segment | Segment			2
Revenue	$ 51,406,000	$ 51,101,000	$ 153,922,000	$ 120,043,000
Excise duties	$ 4,213,000	$ 2,931,000	$ 13,325,000	$ 8,707,000
Customer Concentration Risk [Member] | Revenue [Member] | Customer A [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	21.00%	20.00%	20.00%	12.00%
Customer Concentration Risk [Member] | Revenue [Member] | Customer B [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	19.00%	14.00%	18.00%	11.00%
Customer Concentration Risk [Member] | Revenue [Member] | Customer C [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage		10.00%	11.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer A [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage			20.00%		20.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer B [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage			11.00%		10.00%
Intersegment Sales or Transfers [Member]
Segment Reporting Information [Line Items]
Revenue			$ 0

Business Segment Information _2

Business Segment Information - Summary of Revenue and Gross Profit of each Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 51,406	$ 51,101	$ 153,922	$ 120,043
Gross profit / (loss)	3,739	15,853	9,190	33,511
Cannabis [Member]
Segment Reporting Information [Line Items]
Revenue	31,426	35,451	92,373	78,876
Gross profit / (loss)	(4,717)	9,225	(13,863)	16,213
Hemp [Member]
Segment Reporting Information [Line Items]
Revenue	19,980	15,650	61,549	41,167
Gross profit / (loss)	$ 8,456	$ 6,628	$ 23,053	$ 17,298

Business Segment Information _3

Business Segment Information - Summary of Revenue and Gross Profit (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting [Abstract]
Gross profit	$ 3,739	$ 15,853	$ 9,190	$ 33,511
General and administrative expenses	12,665	20,122	49,030	49,618
Sales and marketing expenses	10,000	16,974	40,709	39,161
Research and development expenses	921	2,315	2,831	4,891
Depreciation and amortization expenses	3,425	3,200	10,353	7,457
Stock-based compensation expenses	8,080	8,644	23,404	22,303
Impairment of assets			58,210
Acquisition-related expenses (income), net		(13,454)		(6,566)
Loss from equity method investments	1,420	1,837	4,495	1,837
Foreign exchange (gain) loss, net	(9,319)	2,585	5,424	1,153
Change in fair value of warrant liability	(31,913)		51,275
Interest expenses, net	10,437	8,680	30,147	26,005
Finance income from ABG		(210)		(557)
Other expense (income), net	(38)	(1,116)	4,944	(6,185)
Loss before income taxes	$ (1,939)	$ (33,724)	$ (271,632)	$ (105,606)

Business Segment Information _4

Business Segment Information - Summary of Sources of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenues	$ 51,406	$ 51,101	$ 153,922	$ 120,043
Dried Cannabis [Member]
Segment Reporting Information [Line Items]
Revenues	21,079	29,412	61,339	62,214
Cannabis Extracts [Member]
Segment Reporting Information [Line Items]
Revenues	10,239	5,819	30,246	16,172
Hemp Products [Member]
Segment Reporting Information [Line Items]
Revenues	19,980	15,650	61,549	41,167
Accessories And Other [Member]
Segment Reporting Information [Line Items]
Revenues	$ 108	$ 220	$ 788	$ 490

Business Segment Information _5

Business Segment Information - Summary of Channels of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 51,406	$ 51,101	$ 153,922	$ 120,043
Cannabis [Member]
Segment Reporting Information [Line Items]
Revenue	31,426	35,451	92,373	78,876
Cannabis [Member] | Adult-use [Member]
Segment Reporting Information [Line Items]
Revenue	19,926	15,835	58,466	38,758
Cannabis [Member] | Canada - medical [Member]
Segment Reporting Information [Line Items]
Revenue	3,399	3,898	11,285	9,222
Cannabis [Member] | International - medical [Member]
Segment Reporting Information [Line Items]
Revenue	8,101	5,708	22,220	9,370
Cannabis [Member] | Bulk [Member]
Segment Reporting Information [Line Items]
Revenue		10,010	402	21,526
Hemp [Member]
Segment Reporting Information [Line Items]
Revenue	$ 19,980	$ 15,650	$ 61,549	$ 41,167

Business Segment Information _6

Business Segment Information - Summary of Revenues Attributed to a Geographic Region Based on the Location of the Customer (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenues	$ 51,406	$ 51,101	$ 153,922	$ 120,043
CANADA [Member]
Segment Reporting Information [Line Items]
Revenues	29,475	33,585	86,807	81,138
UNITED STATES [Member]
Segment Reporting Information [Line Items]
Revenues	13,340	10,836	43,851	28,407
Other Countries [Member]
Segment Reporting Information [Line Items]
Revenues	$ 8,591	$ 6,680	$ 23,264	$ 10,498

Business Segment Information _7

Business Segment Information - Summary of Long-lived Assets Consisting of Property, Plant and Equipment, Net of Accumulated Depreciation, Attributed to Geographic Regions Based On Their Physical Location (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 187,630	$ 184,217
CANADA [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	115,711	144,065
Portugal [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	67,198	36,908
UNITED STATES [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	4,659	3,171
Other Countries [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 62	$ 73

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Kiaro Brands Inc $ in Thousands	Oct. 13, 2020$ / shares	Sep. 30, 2020USD ($)shares
Subsequent Event [Line Items]
Investment owned, Shares | shares		8,532,243
Investment owned, Amount | $		$ 3,600
Subsequent Event
Subsequent Event [Line Items]
Share issued price | $ / shares	$ 0.17